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Abstract 
 
A characteristic feature of Chronic Obstructive Pulmonary Disease (COPD) is an 
abnormal inflammatory response in the lungs to inhaled particles or gases. The 
ability to assess and monitor this response in the lungs of COPD patients is 
important for understanding the pathogenic mechanisms, but also provides a 
measure of the activity of the disease. Disease activity is more likely to relate to 
lung inflammation rather than the degree of airflow limitation as measured by the 
FEV1. Preliminary studies have shown the 18F fluorodeoxyglucose positron emission 
tomography (18F FDG-PET) signal, as a measure of lung inflammation, is 
quantifiable in the lungs and is increased in COPD patients compared to controls. 
However, the methodology requires standardisation and any further enhancement of 
the methodology would improve its application to assess inflammation in the lungs. 
 
I investigated various methods of assessing FDG uptake in the lungs and assessed 
the reproducibility of these methods, and particularly evaluated whether the data 
was reproducible or not in the COPD patients (smokers and ex-smokers). This data 
was then compared with a group of healthy controls to assess the role of dynamic 18F 
FDG-PET scanning as a surrogate marker of lung inflammation. 
 
My data showed a good reproducibility of all methods of assessing FDG lung 
uptake. However, using conventional Patlak analysis, the uptake was not statistically 
different between COPD and the control group. Encouraging results in favour of 
COPD patients were nonetheless shown using compartmental methods of assessing 
the FDG lung uptake, suggesting the need to correct for the effect of air and blood 
(tissue fraction effect) when assessing this in a highly vascular organ like the lungs. 
 
A prospective study analysis involving a bigger cohort of COPD patients would be 
desirable to investigate this further.
Lay Summary 
 
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating chronic lung 
disease condition. It is associated with inflammation in the lungs. The ability to 
measure this inflammation in the lung would be helpful in testing novel anti- 
inflammatory drugs in the future. In this study I used imaging techniques which 
combined positron emission tomography (PET) with radioactive tracer and 
computerized tomography (CT) scans to assess lung inflammation in a group of 
COPD patients (smokers and ex-smokers), and compared this to a group of healthy 
volunteers. The study developed a reproducible method to assess lung inflammation 
in the lungs of COPD patients. 
Thesis Overview 
 
The first chapter deals with overview of COPD, including causes, comorbidities and 
pathogenic mechanisms; highlighting the importance of inflammation and the need 
for inflammatory biomarkers. It also gives a synopsis of the current evidence based 
on pre-existing work in the literature, supporting the use of dynamic PET scans 
using radioactive tracers to measure lung inflammation. 
 
Chapter 2 deals with detailed methodology, including details of the study set-up, 
patient characterisation and principles of various methodologies applied to assess 
lung inflammation in my study cohort using FDG labelled PET scans. 
 
Chapter 3 highlights all the findings from my study including demographics of the 
study subjects and results from the feasibility, reproducibility and the comparative 
phases of this study.  This has been subdivided into smaller sections highlighting the 
various ways of assessing lung inflammation including Patlak analyses, 
compartmental modelling and static PET analyses using SUV measurement. A 
section has also been added reporting results to look at the vascular inflammation in 
this cohort, which was performed as a sub-study in this research project. 
 
Finally, Chapter 4 deals with a detailed discussion of all these methodologies, 
including the highlights and the shortcomings of this study and ways to potentially 
improve these methodological challenges in the future. 
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1.1 COPD and its clinical significance 
 
 
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and 
mortality worldwide. It has been projected to move from the sixth to the third most 
common cause of death worldwide by 2020, whilst rising from fourth to third in 
terms of morbidity within the same timeframe [1]. 
 
The prevalence of COPD in the general population is estimated to be around 1% of 
the adult population, but rises sharply amongst those aged ≥40 years. The 
prevalence continues to increase with age [2]. COPD is known to primarily affect 
the lung structure and function, resulting in emphysematous lung tissue destruction 
and large and small airway disease that occur in varying proportions and severity in 
different individuals [3]. 
 
 
1.1.1 Definitions of chronic obstructive pulmonary disease 
 
 
American Thoracic Society/European Respiratory Society consensus definition: 
Having previously developed definitions for COPD separately, the ATS and ERS 
derived a global definition of COPD in their consensus statement in 2004 [3]. This 
highlighted the importance of obstructive spirometry for a diagnosis of COPD and 
stated the criteria for chronic airflow limitation as – "not fully reversible". It 
acknowledges the most common aetiology and local pulmonary pathological 
changes as an "abnormal inflammatory response of the lungs to noxious particles or 
gases". Finally, reflecting current thinking, there is reference to the association with 
"systemic consequences". 
 
The complete definition is as follows: 
 
“Chronic obstructive pulmonary disease (COPD) is a preventable and treatable 
disease state characterised by airflow limitation that is not fully reversible. The 
airflow limitation is usually progressive and is associated with an abnormal 
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inflammatory response of the lungs to noxious particles or gases, primarily caused 
by cigarette smoking. Although COPD affects the lungs, it also produces 
significant systemic consequences.” 
 
Global Initiative for Chronic obstructive lung disease (GOLD) definition: 
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a 
collaborative project of the US National Heart, Lung, and Blood Institute (NHLBI) 
and the World Health Organization (WHO) [4]. Its goals have been to increase 
awareness of COPD and decrease morbidity and mortality from this disease. GOLD 
aims to improve prevention and management of COPD through a concerted 
worldwide effort of people involved in all facets of healthcare and healthcare policy, 
and to encourage a renewed research interest in this extremely prevalent disease. 
 
This project provides an updated definition of COPD with references to risk 
stratification (exacerbation history and hospital admissions; high risk: two or more 
exacerbations in the preceding 12 months or one or more hospital admissions; low 
risk: one or no exacerbation not leading to a hospital admission and symptom load 
(modified MRC dyspnoea score, [see appendix for table]) [4]. It also focuses on 
the pathological response of the lungs to the injury and the systemic effects and 
associated comorbidities of the condition [4]. 
 
The 2017 GOLD complete definition of COPD is as follows: 
 
“Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and 
treatable disease that is characterized by persistent respiratory symptoms and 
airflow limitation that is due to airway and/or alveolar abnormalities usually 
caused by significant exposure to noxious particles or gases. The chronic airflow 
limitation that is characteristic of COPD is caused by a mixture of small airways 
disease (e.g. obstructive bronchiolitis) and parenchymal destruction (emphysema), 
the relative contributions of which vary from person to person.” 
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The terms 'pink puffer' and 'blue bloater' are now historical, however they were an 
early attempt at describing phenotypes of COPD. Recent studies have begun to 
describe and validate subgroups or phenotypes of this heterogeneous disease that 
have unique prognostic or therapeutic characteristics [5]. 
 
1.1.2 Burden of the disease 
 
Data on mortality from COPD published by the National Records of Scotland shows 
that between 1996 and 2013 the annual number (per 100,000 population) of deaths 
among males where COPD was the underlying cause of death fell, while during the 
same period the rate for females increased. The data also shows that the standardised 
mortality rate (using the 2013 European Standard Population) in the male population 
fell by 32% from 97.6 deaths per 100,000 per year in 1996 to 66.31 in 2013, and in 
females increased by 4% from 48.6 per 100,000 in 1996 to 50.4 in 2013 (Figure 1.1) 
[6]. This is most likely related to improved smoking cessation and better 





Figure 1.1: Mortality rate for COPD as primary underlying cause of death, by 
gender, Scotland 1996-2013 (Data adapted from Scottish Public Health 
Observatory [6]). 
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Despite this, COPD continues to be a major burden on healthcare services and is a 
major cause of mortality both in the UK and worldwide. [1,7]. The National Institute 
for Clinical Excellence (NICE) estimates that COPD accounts for £800 million in 
healthcare costs and is the cause of 90,000 admissions per year, with an average 
length of stay of 11 days [8]. Furthermore, 31% of patients will be readmitted within 
90 days of their discharge. The 2012-2013 data also shows that approximately about 
150,000 COPD patients reside across Scotland (3.8% of the adult pollution). 
 
The trend for admissions due to COPD is to rise as well, with emergency admissions 
due to COPD increasing in Scotland by 2.5-fold in 2006 compared to 1981 (Figure 
1.2) [9]. This change is particularly marked in females most likely because of the 
changes in incidence of smoking, which, whilst going down in males, shows an 




Figure 1.2: Number of people with at least one emergency admission with a 
principal diagnosis of COPD per 100,000 populations in Scotland, 1998-2008 
((adapted from Scottish Public Health Observatory, 2010). 
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1.2 Causes of COPD 
 
 
1.2.1 Cigarette smoking 
 
 
Cigarette smoking is responsible for at least 90% of all cases of COPD. Fifteen to 
twenty per cent of cigarette smokers could develop clinically significant COPD [10]. 
Abstaining from this is clearly related to lower prevalence of tobacco related 
diseases such as COPD [11]. Despite health promotion campaigns worldwide, the 
prevalence of cigarette smoking globally continues to increase. 
 
Fletcher and colleagues described the effect of smoking on lung function in the 
1960s [12]. They described an increase in the decline in the forced expiratory 
volume in the first second (FEV1) in working men of 18mls/year in smokers in 
comparison with non-smokers. 
 
Kohansal et al also described lung function changes in healthy never-smoking males 
and females, from adolescence to old age, and in smokers also to determine the 
effects of this and quitting [13]. This was a prospective cohort study in all 
participants of the Framingham Offspring cohort who had two or more valid 
spirometry measurements during follow-up (n = 4391; age range at baseline 13 to 71 
years), with a median follow-up time of 23 years. The study showed that: (i) healthy 
never-smoker females achieved full lung growth earlier than males, and their rate of 
decline with age was slightly, but not significantly, lower; (ii) smoking increases the 
rate of lung function decline, both in males and in females: rate of decline of FEV1 
of 38ml per year in male and 23ml per year in female smokers, compared with 20ml 
and 18ml in non-smoking males and females respectively, and (iii) quitting smoking 
has a beneficial effect on the rate of lung function decline at any age, but it is more 
pronounced in earlier quitters. 
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Compared to active smoking, very little data is available on the role of passive 
smoking in causing COPD. Data from three cross-sectional studies within the 
Obstructive Lung Disease in Northern Sweden (OLIN) database showed that COPD 
prevalence was independently associated with increased environmental tobacco 
smoke (ETS) exposure, related to work and home circumstances [14]. The 
prevalence was associated with increased ETS exposure: 4.2% (no ETS), 8.0% (ETS 
ever at home), 8.3% (ETS at previous work), and 14.7% (ETS ever at home and at 
both previous and current work), and therefore showed that ETS in multiple settings 
was, after age, the strongest risk factor for COPD and comparable to personal 
smoking of up to 14 cigarettes/day. People aged greater than 65 years were excluded 
from this study and ageing therefore could not have contributed to these findings. 
 
With the introduction of indoor smoking bans across Europe and the concurrent 
improvement of respiratory ailments in workers previously exposed to a smoky 
environment, it is anticipated that there will be a reduction in COPD in individuals 
previously exposed passively to cigarette smoke. 
 
 
1.2.2 Inhalation of other noxious substances 
 
 
Cannabis is the most commonly used illicit recreational substance across the globe. 
The drug is most commonly smoked in a hand-rolled cigarette or in a designed 
water pipe; it may also be added to food and eaten. It contains many chemicals 
unique to the plant (referred to as cannabinoids), including the desired psychoactive 
component - delta-9-tetrahydrocannabinol (THC) [15]. Concerns regarding the 
respiratory effects of inhaling cannabis smoke are heightened by the knowledge 
regarding the harm caused by tobacco smoke and the different way in which 
cannabis is smoked. That is, when smoking cannabis compared with tobacco, there 
is a prolonged and deeper inhalation and this inhalation technique results in an 
approximately fivefold increase in carboxyhaemoglobin concentration, fourfold 
greater amount of tar inhaled, and the retention of one third more tar in the lower 
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airways [16]. The presence of bullous lung disease or emphysema therefore has been 
reported among chronic cannabis smokers, although whether the association should 
be considered causal or causative is in contention. An Australian group has also 
described early bullous disease in cannabis smokers that occurs much earlier than in 
cigarette smokers [17] although this has not been confirmed in another study [18]. 
A growing body of literature also supports the impact on lung function of cannabis 
use in terms of developing COPD, most commonly by measuring FEV1 and the 
forced vital capacity (FVC). Using these measures, a few studies have found a 
relationship between regular cannabis use and increased airway obstruction 
compared with those who do not use the product [16, 19]. 
 
While smoking is thus the major cause of COPD, occupational exposures to 
vapours, gases, dusts, and fumes (VGDF) can also increase the risk [20]. There is 
now an abundant support in the literature linking COPD to exposure to dusts in the 
workplace. Groups at particular risk are coal miners and hard rock miners, as well as 
workers exposed to mineral dusts and fine metal articulate such as cadmium and 
vanadium. Dement et al showed an 18% increased risk attributed to construction- 
related exposures, which are additive to the risk contributed by smoking [21]. 
 
In the developing world, indoor wood and other biomass fuel burning stoves have 
also been implicated as a causal factor in the development of COPD, particularly in 
women engaged in household work [22]. 
 
 
1.2.3 Genetic implications 
 
 
Alpha-1-antitrypsin deficiency: This is a well-known causative factor for COPD. 
Alpha-1 antitrypsin (A1AT) is produced in the liver, and one of its functions is to 
protect the lungs from neutrophil elastase, an enzyme that can disrupt connective 
tissue. A1AT deficiency therefore can, in younger people, lead to development of 
emphysematous lung disease [23]. In a minority of cases of COPD, deficiency of the 
antiprotease α-1-antitrypsin (AAT), which is an autosomal recessive disease, could 
9  
be the causative factor [24]. The primary function of the anti-protease AAT is to 
inhibit neutrophil elastase. In severe deficiency, anti-elastase protection in the lung 
interstitium and alveolar space is markedly decreased to about 15-20% of normal 
levels, similar to the decrease in plasma levels. An imbalance of elastase and anti- 
elastase, along with increased innate inflammation in the lung that increases the 
elastase burden, is believed to cause lung destruction resulting in emphysema in  this 
disease. It is now apparent that AAT has important immune-regulatory roles that 
would be lost in AATD [25]. Beraldo et al [26] showed that the adaptive immune 
inflammation, comprising B, CD4 (+), and CD8 (+) lymphocytes, and lymphoid 
follicles, is a prominent feature in AATD. These results change the paradigm of the 
mechanism of AATD-induced emphysema from a pure elastase/anti-elastase 
imbalance to a much more complex one involving the adaptive immune system, 
similar to that which occurs in usual COPD. 
 
Genetic influences on lung function as measured by FEV1 and consequent increased 
risk of developing COPD have been reported from twin and family studies [23]. In 
one such study, Zhai and colleagues [23] studied unselected monozygotic (MZ) and 
dizygotic (DZ) twin pairs from the Twins UK registry to estimate the heritability of 
the ratio of measured FEV1 (mFEV1) to expected FEV1 (eFEV1) in a white 
population, and to examine the interaction between genetic factors and smoking on 
this ratio. The heritability estimate for mFEV1/eFEV1 ratio was 66% in non-smokers 
but was significantly reduced to 32% in current smokers. No clear difference was 
found in the heritability of this ratio between non-smokers and ex-smokers, 
suggesting that genetics could be a major influence in non-smokers. However, this 
genetic influence indeed could be further amplified in a major way by interaction 
with external factors such as cigarette smoking. 
 
Other genetic influences: Silverman et al studied a cohort of 44 probands with 
severe, early-onset COPD, who did not have severe alpha-1-antitrypsin deficiency in 
a population [25]. This cohort had a high prevalence of females (79.6%) and the 
study found that the first-degree relatives of early-onset COPD probands had 
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significantly lower FEV1 and FEV1/FVC values than control subjects (p<0.01), 
despite similar pack-years of smoking. Reduced spirometric values in these relatives 
of early-onset COPD probands were seen only in current or ex-cigarette smokers, 
indicating that the incidence of the disease is possibly higher in the first- degree 
relatives of the COPD patients, and also reinforces the detrimental additive effect of 
cigarette smoking in this group. 
 
Data from the COPDGene and ECLIPSE studies also show that there could be 
genetic differences between subjects with various phenotypes of COPD (eg, the 
chronic bronchitis [CB] phenotype) [27]. One such study showed that the CB 
phenotype of COPD relative to smoking controls is more common in a new genome-
wide significant locus on chromosome 11p15.5, as well as with significant 
associations of known COPD single-nucleotide polymorphisms within the FAM13A 
gene. This provides further evidence that genetic variants may also contribute to 
phenotypic heterogeneity of COPD. 
 
 
1.2.4 Childhood risk factors 
 
 
There are several well-known associations with risk factors in childhood and 
development of COPD in later life. 
 
Poor socioeconomic status along with adverse childhood experiences (ACEs) 
before age 18 has been associated with several chronic diseases in adulthood, 
including COPD [28]. Cunningham et al [28] studied data from a large cohort of 
adults and used a regression analysis model to estimate prevalence ratios and their 
corresponding 95% confidence intervals (CIs) for the relationship of eight ACEs 
with COPD after adjustment for age group, race/ethnicity, marital status, 
educational attainment, employment, asthma history, health insurance coverage, and 
smoking status. The data showed that 63.8% of women and 62.2% of men reported 
≥1 ACE. 4.9% of women and 4.0% of men reported COPD. In women, but not in 
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men, there was a higher likelihood of COPD-associated variety of childhood adverse 
experiences. There was a higher likelihood of COPD associated with verbal abuse 
(PR =1.30, 95% CI: 1.05, 1.61), sexual abuse (PR =1.69, 95% CI: 1.36, 2.10), living 
with a substance abusing household member (PR =1.49, 95% CI: 1.23, 1.81), 
witnessing domestic violence (PR =1.40, 95% CI: 1.14, 1.72), and parental 
separation/divorce (PR =1.47, 95% CI: 1.21, 1.80) during childhood compared to 
those with no individual ACEs. Reporting ≥5 ACEs (prevalence ratio =2.08, 95% 
CI: 1.55, 2.80) compared to none was associated with a higher likelihood of COPD 
amongst women, reinforcing the need for the need for further research that examines 
sex-specific differences and the possible mechanisms that links ACEs and COPD. 
 
Childhood respiratory infections: both viral and bacterial infections are important 
risk factors for the pathogenesis of COPD.  Several recent cohort studies suggest 
that lung growth is impaired by childhood lower respiratory tract infection, making 
these individuals more vulnerable to developing COPD on exposure to additional 
risk factors [29]. The majority of these childhood infections are viral in origin, such 
as adenovirus, that appear to persist as latent infections in the airways of patients 
with COPD, and adenoviral E1A protein is capable of amplifying host genes, 
possibly including those involved in cigarette smoke-induced lung inflammation at  
a later stage in life [30]. In this context a DNA virus, adenovirus (Ad), early gene 
1A (ElA gene) has been identified in lung tissue of COPD. The E1A gene 
expression can augment the soluble intercellular adhesion molecule (ICAM) 1 
expression and the recruitment of inflammatory cells into airways of COPD lungs 
[30]. 
 
Similarly, low birth weight has been reported as a poor prognostic marker for 
development of adult respiratory diseases including COPD. Barker and colleagues 
reported an association between low birth weight and adult respiratory function, and 
this relationship appeared to be present in all socioeconomic classes [31] and was 
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also associated with death from COPD. Stern et al also investigated whether lung 
function in early adulthood is affected by airway function measured shortly after 
birth [32]. This study showed that the participants who had infant Vmax (maximal 
flow at functional residual capacity) in the lowest quartile also had lower values for 
the FEV1/FVC ratio (-5.2%, p<0.0001), FEF25-75 (-663 mL/s, p<0.0001), and 
FEV1 (-233 mL, p=0.001) up to age 22, after adjustment for height, weight, age, and 
sex, than those in the upper three quartiles combined. This suggests that very early 
life factors can have a big impact on the development of airways disease in the 
future. Similarly the Danish Inter99 study looked at adults aged 30-60 years, 
providing information on birth weight and lung function on 4428 participants [33]. 
The study showed that birth weight was positively associated with spirometric 
variables: for a 1 kg increase in birth weight, FEV1 increased by 86 ml (95% CI: 34-
139) and FVC by 88 ml (95% CI 27-148); again showing the negative implication of 
low birth weight in the potential development of COPD at a later life. 
 
1.3 Pathogenesis of COPD 
 
 
The pathogenesis of COPD is thought to be multifactorial [34] and inflammation 
plays a major role. 
 
Table 1.1 summarises the important factors causative in the pathogenesis of COPD 






















Table 1.1 summarises all the pathogenic mechanisms in causing COPD 
 
Mechanism Pathogenic contribution in COPD 
Oxidative stress Circulating inflammatory cells produce reactive 
oxygen species (ROS) promoting inflammation [35] 
Role of premature ageing 
(senescence) 
• Shortened telomere length is associated with 
reduced lung function emphysema and 
increased risk of COPD [36] 
• Senescence markers P16/p21/s-β gal are 
increased in COPD lungs [37] 
• Reduced level of anti-ageing molecules SIRT1 
and Klotho in lungs of COPD patients [38-39] 
Inflammation In COPD patients - 
Neutrophils: show enhanced ROS production [18] 
Monocytes: have defective phagocytosis, increase 
matrix metalloproteinase (MMP)-9 release [40] 
Lymphocytes: peripheral blood T cells show 
increased apoptosis and Senescent T-cell 
phenotype [40] 
NK cells: Reduction of cytotoxic and phagocytic 
function [40-42]. 
Persistent high levels of systemic and pulmonary 
IL6, TNFα and acute phase reactants such as CRP, 
Fibrinogen and surfactant protein D seen in COPD 
[40] 
Advanced glycation end- 
product (AGE) 
COPD patients have lower levels of circulating 
AGEs 
correlating with the presence of emphysema [43] 
Protease–antiprotease 
imbalance 
Leads to lung parenchymal destruction [44] 
Autoimmune Hypothesis The hypothesis is that COPD has an autoimmune 
component that may account for the persistent 
enhanced airway inflammation that develops with 
exposure to cigarette smoke [45] 
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The following section will discuss some of these aspects in greater detail. 
 
 
1.3.1 Pulmonary inflammation 
 
 
Chronic lung inflammation is a characteristic feature of COPD and plays a key role 
in the pathogenesis of the disease. This involves a number of cells including 
neutrophils, macrophages, T lymphocytes and augmented concentrations of 
proinflammatory mediators such as leukotriene B4, Interleukin (IL)-1, IL-6 and IL- 
8b and TNF-α [32]. Bronchoalveolar lavage fluid and sputum have also been shown 
to demonstrate increased levels of inflammatory biomarkers such as cytokines, 
soluble cytokine receptors and proteases in COPD patients [46]. 
 
An exaggerated inflammatory response of the airways to chronic irritants, primarily 
cigarette smoke, is thus an important feature of COPD. After smoking cessation, this 
inflammation can persist and the levels of pro-inflammatory cytokines in the lungs 
and bloodstream remain high in many patients with COPD, even those with mild 
and stable forms of the disease [47]. 
 
Pulmonary emphysema has also been shown to be associated with increased activity 
of proteolytic enzymes, which are activated due to inflammation and oxidative stress 
occurring in COPD [48]. Mucus hyper secretion, a feature predominantly of the 
chronic bronchitic phenotype of COPD has been associated with an increased 
number of exacerbations, and is associated with increased inflammation around the 
submucosal glands as well as enhanced severity of inflammation in peripheral 
airways [49]. Chronic lung inflammation in COPD can thus result in remodelling of 
the airways (small airways disease) and destruction of the lung parenchyma 
(emphysema). This persistent lung inflammation is therefore considered a major 
driver of COPD progression. 
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In addition, systemic inflammation, present in a proportion of COPD patients, may 
also contribute to the development of systemic complications of COPD [50] that 
adversely affect clinical outcomes. Agusti et al showed that persistent systemic 
inflammation, defined as having two or more elevated blood inflammatory 
biomarkers (high sensitivity CRP, IL-6, white blood cell count, fibrinogen) on two 
occasions one year apart, occurred in a proportion of COPD patients (16%) and was 
associated with worse clinical outcomes, including increased mortality [51]. Lung 
and systemic inflammation are further amplified during exacerbations of COPD and 
hence are of great importance in risk stratification [52]. 
 
There is much debate around whether the systemic inflammation in COPD arises 
from a "spill-over" of inflammatory mediators from lung inflammation [40, 51-53], 
or whether the systemic inflammation in COPD represents a systemic component of 
the disease that develops in parallel with, or prior to, pulmonary inflammation [50]. 
The absence of a relationship between inflammatory biomarkers in the sputum and 
blood of COPD patients has provided some evidence against the "spill-over theory" 
[54, 55]. Smoking, lung hyperinflation, tissue hypoxia, skeletal muscle, bone 
marrow stimulation, immunological disorders, and infections are all cited as 
possible sources of systemic inflammation in COPD [56]. Thus, this is now 
considered a systemic effect of COPD as well and will be explained in more detail 
in section 1.4. 
 
 
1.3.2 Oxidative stress 
 
 
Oxidative stress reflects an imbalance between the manifestation of oxidants and the 
ability of a biological system to detoxify these reactive oxidants or to repair the 
resulting damage. There is good evidence that such an imbalance between oxidants 
and antioxidants occurs in patients with COPD and is another major driver force in 
the pathogenesis of the disease in conjunction with inflammation [57]. Increased 
levels of biomarkers of oxidative stress have been shown to be present in COPD 
16  
patients in many studies [58]. An increased level of 8-hydroxy-deoxyguansoine, a 
marker of oxidative DNA damage, is present in peripheral lung tissue of smokers 
(with and without COPD) compared with non-smokers [59]. Increased expression of 
8-hydroxydeoxyguanosine (8-OHdG), an oxidized nucleoside of DNA, leads to 
further generation of ROS, diminished DNA auto-repair ability and ultimately 
somatic mutations even after smoking cessation, thus promulgating further 
inflammation. Raised levels of 3-nitrotyrosine a marker of nitrosive stress and the 
lipid peroxidation product F2α isoprostanes have also been detected in the lungs of 
COPD patients, and these showed a strong correlation with the severity of airflow 
limitation as measured by FEV1 in COPD patients [60]. Other studies have shown 
increased levels of the lipid peroxidation product 4-hydroxynonenol in the lungs of 
COPD patients compared with smokers who have not developed COPD [61]. 
Increased markers of oxidative stress are also found systemically in COPD patients 
[62]. Thus, increased oxidative stress is a feature in COPD lungs and systemically in 
COPD patients and is a major driver of the pathogenesis of the disease in 
conjunction with inflammatory processes. 
 
 
1.3.3 Protease-antiprotease imbalance in COPD 
 
 
The interactions between Reactive Oxygen Species (ROS), proteases and 
antiproteases can trigger a protease/antiprotease imbalance leading to lung 
parenchymal destruction and emphysema [44, 63]. This protease/ antiprotease 
imbalance is thought to result from an increased release of proteases by 
inflammatory cells and from oxidative inactivation of protease inhibitors [64, 65]. 
Smoke exposure from cigarettes or other biomass smoke can inactivate endogenous 
antiproteases, activate resident alveolar macrophages and promote neutrophil  influx 
into lungs [63, 66]. This is therefore an important adjunct mechanism to the 
inflammation and oxidative stress observed in COPD. These activated leukocytes 
release proteases, such as neutrophil elastase, proteinase 3, matrix 
metalloproteinases (MMPs), and cathepsins [63]. These proteinases act as 
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potentiators of each other and also impede the action of their endogenous inhibitors 
[63, 67]. These proteinases act on components of the extracellular matrix, elastin 
fibres and collagen and produce chemotactic peptide fragments that attract the 
further macrophage and neutrophil influx and lung damage. 
 
This imbalance could further be triggered by infection and bacterial colonization. 
Sethi and colleagues studied 39 consecutive COPD patients in a prospective 
observational study and identified 76 acquisitions of a new strain of M. catarrhalis in 
sputum over a 6-year period [68]. Pre-acquisition sputum supernatant samples, 
obtained just before acquisition of M. catarrhalis, and post-acquisition samples 
(associated with exacerbation and some with colonization) were analyzed for IL-8, 
TNF-α, Neutrophil Elastase (NE) and Secretory leukocyte protease inhibitor (SLPI). 
IL-8, TNF-α and NE were significantly elevated after acquisition of M. catarrhalis, 
compared to pre-acquisition samples (p=<0.001 for all three). These inflammatory 
biomarkers were also present in colonization (p=0.015 for IL-8; p=<0.001 for TNF-
α and NE) as well as in exacerbation (p=<0.001 for all three), compared to pre- 
acquisition levels. SLPI was significantly lower after acquisition (p=<0.001), in 
colonization (p=<0.001) as well as in exacerbation (p=0.004), compared to pre- 
acquisition levels. This is an important study as this further confirms that there is 
increased airway inflammation and worsening protease-antiprotease imbalance can 
happen during exacerbations and also in sputum colonization, adding to the 
inflammatory cascade of the disease pathogenesis and progression. 
 
 
1.3.4 Accelerated ageing 
 
 
Telomere length shortening in COPD: Evidence suggests that there is occurrence 
of premature senescence in COPD patients [36]. 
 
In many human somatic tissues and cells including lung fibroblasts, there is a 
progressive waning in cellular division capacity with age or a restricted division 
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potential before undergoing so-called "replicative senescence". This process is 
linked to the fact that the telomeres, which protect the ends of chromosomes, get 
progressively shorter as cells divide. 
 
Telomeres are repetitive DNA sequences (TTAGGG/CCCTAA) located at the end 
of chromosomes, protecting chromosomes against degradation and remodelling 
[69]. Due to the end-replication problem in mature somatic cells, telomere repeats 
are lost with each replicative cycle, until a critical length is attained when the cells 
undergo senescence. Inflammation or oxidative stress can amplify this process 
significantly leading to shortened telomere length [70]. Assessing telomere length is 
therefore considered to be a marker of biological age. 
 
As a part of the Lung Health Study, 5887 smokers, aged 35-60 years with mild to 
moderate airflow limitation were recruited across North America [71]. In this cohort 
telomere length of peripheral blood leukocytes of patients with COPD was 
significantly related to the risk of all-cause (Hazard Ratio, HR, 1.29; p=0.0425) and 
cancer mortality (HR, 1.48; p=0.0324) over a median follow-up of 7.5 years, 
irrespective of potential confounders such as chronological age, smoking status and 
lung function [72]. 
 
In another observational study, Rode et al studied almost 10,000 patients with 
COPD and performed telomere length analysis on peripheral blood leukocytes and 
showed that telomere length decreased significantly with increasing age and with 
decreased FEV1/FVC ratio, indicating a relationship between telomere length and 
the degree of airflow limitation [36]. Sin and colleagues had also shown similar 
results in another cohort of patients [73]. Interestingly, Debigaire et al has also 
recently shown shortened telomere length from the quadriceps muscle biopsy of 
COPD patients compared to healthy subjects, suggesting a role of premature ageing 
in the observed muscle dysfunction in COPD [74]. This study reinforces that in 
COPD patients accelerated ageing plays an important role in pathogenesis of the 
disease as well as disease progression. 
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Cigarette smoking may play an important role in this accelerated aging process. 
Animal studies have shown that animals with shorter telomeres in their lung cells 
have increased susceptibility to cigarette smoke-induced emphysema [75]. Studies 
also have shown that in circulating leukocytes, both current and ex-smokers had 
shorter telomeres than their age-matched non-smokers with a dose-dependent 
relationship between the telomere length and the years smoked, and that telomere 
length in COPD patients were shorter than that of control subjects in any age range 
[76]. 
 
In this context of accelerated aging in COPD, sirtuins deserve a special mention. 
 
 
Sirtuins are Type III histone deacetylases (HDAC) that act on histone residues in 
DNA that regulate various cellular processes, such as cell cycle differentiation, 
apoptosis, autophagy and senescence [77, 78]. Within the histone deacetylases 
(HDACs), sirtuins maintain a special position since they are structurally different 
from other HDACs and are inhibited by different compounds as they have the 
unique characteristic of being NAD+-dependent [79]. Amongst the sirtuins, sirtuin1 
(SIRT1) is important in the context of COPD and is thought to be involved in the 
clearance of old and damaged mitochondria by prompting autophagy.  It also aids in 
the activation peroxisome proliferator-activated receptor γ coactivator-1α (PGC- α), 
the mitochondrial biogenesis regulator, and thereby facilitates the recruitment of 
new mitochondria [80]. Given the central role of mitochondria in the ageing process 
[81, 82], activation of Sirt1 by maintaining and potentially rejuvenating the pool of 
mitochondria is a potential therapeutic option. In this respect, resveratrol (3, 4′, 5- 
trihydroxystilbene), a plant polyphenol, deserves mention [83]. Resveratrol appears 
to facilitate its anti-ageing effects partly by stimulating SIRT1 and is also reported to 
be a powerful antioxidant as well as with anti-inflammatory properties (PI3K 
inhibitor). This is of clinical significance in COPD as a potential anti-inflammatory 
and an anti-ageing agent given the observed levels of reduced SIRT1 in the COPD 
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lungs and the associated premature ageing and inflammatory burden as observed in 
this cohort [83]. 
 
Advanced glycation end products (AGEs): Though not directly implicated in the 
pathogenesis of COPD, advanced glycation end products (AGEs) also deserve a 
mention as a potential contributor to the inflammatory disease load. 
 
Advanced glycosylation end products of proteins (AGEs) are non-enzymatically 
glycosylated proteins, which accumulate in vascular tissue with age [84]. AGEs 
have a broad range of cellular functions, especially in endothelial cells and 
macrophage expression of procoagulant activity, inducing migration of mononuclear 
phagocytes, as well as production of platelet derived growth factor and cytokines 
[84, 85] adding to the inflammatory cascade. 
 
The receptor for advanced glycation end products (RAGE) is a multi-ligand signal 
transduction receptor that can initiate and propagate inflammation induced by a 
variety of stimuli including hyperglycaemia, oxidative stress, ageing and hypoxia 
[86]. RAGE has several isoforms including a soluble form known as sRAGE that 
appears to act as a decoy receptor, binding RAGE ligands in the extracellular fluid 
and thus providing protection against inflammation and oxidative stress [84] and so 
is a potential therapeutic target. 
 
A recent study showed that membrane RAGE is overexpressed in the airway smooth 
muscles and epithelium of COPD patients [87]. Acute exacerbations of COPD were 
associated with further reductions in plasma sRAGE and high serum CRP 
concentrations. Miniati and co-workers in another study involving a large group of 
COPD patients and age- and sex-matched controls showed that a decrease in 
sRAGE in COPD was strongly associated with the impairment of lung diffusing 
capacity, and the severity of emphysema measured by CT scanning [43]. 
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In this context, high mobility group protein B1 (HMGB1) an abundant chromatin 
protein that acts as a cytokine when released into the extracellular milieu by necrotic 
and inflammatory cells deserves a mention.  It is considered a marker of tissue 
injury and a mediator of inflammation.  Recent studies also report an enhanced level 
of HMGB1 in BAL fluid, sputum and in blood in patients with COPD [87]. sRAGE 
presumably inhibits the activity of HMGB1, and therefore might be of potential 
therapeutic importance in breaking the inflammatory cascade that contributes to 
accelerated ageing in COPD. 
 
 
1.3.5 Autoimmune hypothesis 
 
 
Autoimmune conditions are characterised by B- and T-cell responses to self- 
epitopes and thus the demonstration of B-cell immunoglobulin production and/or T-
cell reactivity against autologous antigens is a defining feature of autoimmunity. An 
autoimmune hypothesis has also been suggested in the pathogenesis of COPD. Lee 
and colleagues described anti-elastin antibodies in a cohort of emphysematous 
patients in comparison with a non-emphysematous control group [88]. In addition, 
they also reported enhanced T-helper cell responses in the emphysema cohort to 
elastin peptides in comparison with healthy controls and an asthmatic control 
population, with the production of both interferon-gamma and IL-10. Both cytokines 
were closely associated with CT-quantified emphysema severity. The authors 
suggested that exposure to cigarette smoke leads to proliferation and activity of B- 
and T-cells against elastin that propagates inflammation after withdrawal of the 
cigarette smoke stimulus. 
 
This is an interesting theory as it could provide an explanation as to why airway 
inflammation that develops with exposure to cigarette smoke persists following the 
cessation of smoking [89]. Furthermore, it may explain why some smokers are more 
susceptible to lung damage on exposure to cigarette smoking. Finally, the 
autoimmune theory might help us understand the development of COPD as a 
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condition with extra-pulmonary effects as is observed in this cohort, in a similar way 





1.4.1 Systemic effects of COPD and co-morbidities 
 
 
Besides the lung abnormalities, COPD is now recognised as a condition that has an 
impact on other organs, the so-called "systemic effects" and comorbidities of COPD 
[32, 39, 44]. Conventionally, comorbidity has been defined as a disease coexisting 
with the primary disease of interest. In COPD, however, the definition becomes 
even more challenging, as certain coexisting illnesses may be a consequence of the 
patients' underlying COPD [90]. 
 
It is as yet unclear whether these associations are a consequence of shared risk 
factors such as cigarette smoking and poor physical activity, or whether COPD is a 
true causal factor. Nevertheless, these extra-pulmonary features of COPD add to the 
challenge of assessing and managing the disease and to the added burden of 
inflammation. 
 





Systemic effects of COPD [32, 39, 
44] 
Comorbidities in COPD [32, 39, 44] 
• Muscle dysfunction 
• Cachexia 
• Autonomic dysfunction 
• Systemic inflammation 
• Cardiovascular co- morbidities 
• Lung cancer 
• Osteoporosis 
• Nutritional abnormalities 
• Anaemia 
• Diabetes 
• Psychological issues 
• Obstructive sleep apnoea 
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1.4.2 Systemic inflammation 
 
 
Although more an association interlinked with pulmonary inflammation than a 
causative effect in the pathogenesis of the disease and its extra pulmonary effects, it 
is nonetheless important to understand the effects of systemic inflammation in 
COPD [45]. 
 
Several recent studies have clearly shown that COPD is associated not only with an 
abnormal inflammatory response of the lung parenchyma, but also with evidence of 
systemic inflammation, including systemic oxidative stress, activation of circulating 
inflammatory cells and increased levels of pro-inflammatory cytokines [33, 34]. 
 
This inflammatory response is thus similar to that observed in the lung, and this 
concept is key to understanding the development of the various systemic effects as 
seen in this disease. 
 
Systemic inflammation has been implicated as a causative factor for many of the 
systemic manifestations and the comorbidities of the disease [32]. In a systematic 
review of 14 original studies, Gan and co-workers demonstrated that peripheral 
blood leukocyte count and C-reactive protein (CRP) levels were raised in COPD 
patients, compared to smokers without COPD [91]. Systemic inflammation may 
thus also contribute to the extra-pulmonary features associated with COPD, such as 
skeletal muscle dysfunction, osteoporosis and an increased risk of cardiovascular 
disease, and these in turn can add to the inflammatory burden of COPD. 
 
 
Figure 1.3 summarises these interrelations between inflammation and the co- 
morbidities and systemic effects in COPD. 
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Figure 1.3: shows interchanging role of systemic inflammation in COPD as a 
cause and an effect of disease pathogenesis. 
 
 
Table 1.3 summarises the predominant mediators that have been implicated in 
causing the systemic inflammation in COPD and also responsible for the 




Cytokines IL6  (↑) Cardiovascular and skeletal muscle 
dysfunction [92] 
TNF-α  (↑) Metabolic and skeletal muscle 
dysfunction [93, 94] 
IL-1β  (↑) Cachexia in COPD [44] 
CXCL8 (IL-8) and other 
CXC chemokines  (↑) 
Neutrophil and monocyte recruitment and 
also contributes to SMD [44] 
Adipokines such as 
leptins  (↑) 
Possible role in cachexia in COPD [44] 
Acute phase 
proteins 
CRP  (↑) Raised in infective exacerbations 
potentiates cardiovascular effects and 
SMD [32, 95] 
Fibrinogen  (↑) Raised in COPD associated with 
cardiovascular complications [96, 97] 
Surfactant protein D (↓) Derived from lung tissue, circulating 
levels of this is inversely associated with 
lung function and health status of patients 
with advanced COPD [98] 
Serum amyloid A (SA-A) 
(↑) 
Released by circulating pro-inflammatory 
cytokines, SA-A levels are raised during 
acute exacerbations of COPD and its 
concentrations are correlated with the 
severity of exacerbation [99] 
Circulating 
cells 
Neutrophils (↑) Inverse correlation between neutrophil 
numbers in the circulation and FEV1 [100], 
increased turnover in smokers [44], 
enhanced production of reactive oxygen 
species [101] 
Monocytes (↑) Increase macrophage accumulation in the 
lungs with defective phagocytosis [44], 
increase matrix metalloproteinase (MMP)-
9 levels in the lungs in COPD compared 
to non-smokers [102] 
Lymphocytes (↑) Increased apoptosis of peripheral T 
lymphocytes from COPD patients, with 
increased expression of Fas. TNF- α and 
transforming growth factor (TGF)- β 
[44,103], increase in apoptosis of CD8+ 
T- cells in COPD [104] 
Natural killer cells (NK) 
cells (↓) 
Reduction of cytotoxic and phagocytic 
function of circulating NK cells has been 
reported in COPD [42, 44] 
 
Table 1.3: Inflammatory mediators as observed in COPD 
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Undeniably, inflammation (both local and systemic) plays a major role in the 
pathogenesis of COPD, and makes it all the more pertinent to develop novel 
biomarkers that will help us to quantify the disease burden better and also aid to 
assess the efficacy of newer anti-inflammatory treatments in the future. 
 
 
1.4.3 Comorbidities in COPD 
 
 
Although not directly relevant to this study, a brief understanding of some of the 
comorbidities of COPD may also help us to understand the underlying inflammatory 
cascade that has an implication in the pathogenesis and progression of the disease. 
 
Cardiovascular complication: Cardiovascular disease is the most significant non- 
respiratory contributor to both morbidity and mortality in COPD and has been 
reinforced in many research studies. In one such large cohort of COPD patients 
admitted to a Veterans Administration Hospital or clinic, the prevalence of coronary 
artery disease was 33.6%, appreciably higher than the 27.1% prevalence seen in a 
matched cohort without COPD [105]. In the lung health study that assessed deaths 
and hospitalizations over a 5-year period in a cohort of COPD patients, mortality in 
5,887 patients aged 35 to 46 years with COPD and mild to moderate airways 
obstruction was 2.5%, of which 25% died of cardiovascular complications [106], 
and cardiovascular disease accounted for 42% of the first hospitalisation and 44% of 
the second hospitalisation over a follow up period of 5 years in patients with 
relatively mild COPD. Compared to this, only 14% of the hospitalisations in this 
cohort were from respiratory causes. 
 
Divo and co-workers also studied 1,664 patients with COPD for over 4 years to 
assess COPD comorbidities and mortality risk [107]. They generated a COPD 
comorbidity index based on the comorbidities that increase mortality risk using a 
multivariate analysis. The prevalence of coronary artery disease in this study was 
unsurprisingly high at 30.2%, with congestive heart failure and dysrhythmias 
making up another 15.7% and 13% of the cases respectively, and was strongly 
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associated with an increased risk of death (p value <0.05). 
 
Mannino and co-workers also assessed the prevalence of COPD deaths in the US 
between 1979 and 2001 [108]. They found there were about 47 million hospital 
discharges (8.5% of all hospitalizations in adults) with a primary or secondary 
diagnosis of COPD (21% and 79%, respectively). Hospital mortality was 43% 
related to heart disease, compared to 37% related to respiratory failure and another 
25% related to pneumonia in this combined cohort (primary or secondary diagnosis 
of COPD). 
 
FEV1 is also known to be an independent predictor of cardiovascular complications 
in COPD patients. In the Lung Health Study for every 10% decrease in FEV1, 
cardiovascular mortality increased by approximately 28% and non-fatal coronary 
events increased by approximately 20% in mild to moderate COPD [106]. Even a 
moderate reduction of expiratory flow volumes manifolds the risk of cardiovascular 
morbidity and sudden cardiac deaths by 2-3 times, independent of other risk factors 
[109-112]. COPD patients also have shown evidence of increased atherosclerotic 
plaque burden as assessed by increased carotid intimal medial thickening (CIMT) 
which is associated with increased cardiovascular and all-cause mortality [113]. 
 
Studies have also shown that patients with COPD can have significantly increased 
coronary artery calcification as observed on CT than controls, and this is associated 
with increased dyspnoea, reduced exercise capacity and increased mortality in the 
cohort [114]. In another study, circulating desmosine as a marker of elastin 
degradation showed that excess elastin degradation could relate to cardiovascular 
comorbidities, atherosclerosis, arterial stiffness, systemic inflammation and 
mortality in COPD patients [115]. 
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Vascular inflammation is a well-known manifestation in this cohort and there is 
strong associative evidence that the inflammatory cells and mediators in COPD are 
also relevant to the development of cardiovascular disease and cardiovascular 
complications [56, 112]. In one such study, Sin and colleagues studied around 6,000 
participants and found that in the presence of both elevated high sensitive CRP and 
moderate or severe airflow obstruction, the risk of a cardiac injury was significantly 
higher in the COPD patients than in those without airflow obstruction and with low 
CRP, suggesting contributory effect of low grade inflammation on the risk of 
cardiac injury [112]. This may also explain the 'COPD effect' that contributes to 
increased cardiovascular complications as seen in this condition [56]. 
 
Skeletal Muscle Dysfunction: One of the most striking systemic consequences of 
COPD is the reduction in peripheral muscle mass resulting in muscle wasting and 
dysfunction. Muscle dysfunction, with or without evidence of atrophy, can be 
defined physiologically as the failure to achieve the basic muscle functions of 
strength and resistance, the latter being inversely related to an increase in the 
fatigability of the muscle. 
 
Inflammatory mediators such as TNF-α as well IL-1β and IL8 have been implicated 
in these observed changes [44, 93, 94]. 
 
Reduced quadriceps strength in COPD is associated with reduced exercise capacity 
[116, 117], compromised health status [118], increased need for healthcare resources 
[119] and mortality and was found to be independent of airflow obstruction [120]. 
Skeletal muscle weakness, particularly quadriceps weakness, has also recently been 
shown to be a feature of early disease [121], and its development is likely to be 
multifactorial with inflammation and oxidative stress [122] being the predominant 
factors, coupled with physical inactivity [123, 124]. Several other factors, such as 
protein synthesis/degradation imbalance and hypoxia, have also been postulated to 
explain the initiation and the progression of this muscle wasting in COPD [117, 
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125]. Studies also show that up to one third of COPD patients may present with net 
loss of muscle mass, which is partly responsible for the weight loss in these patients 
[126]. However, muscle wasting can also be present in 6-21% of patients with 
normal weight [126]. Unintentional loss of muscle mass has also shown to have a 
significant impact on quality of life and is associated with premature death [127]. 
 
Skeletal muscle dysfunction has thus been linked to various poor outcomes in 
COPD, including mortality, and has a strong correlation with inflammation. Studies 
have shown that sarcopenia is very common in patients with stable COPD, and is 
associated with more severe dyspnoea scores, lower exercise tolerance and increased 
levels of inflammatory mediators [128]. Other studies have also shown these pro-
inflammatory cytokines to be the key contributors to the loss of skeletal 
muscle mass and the deregulated skeletal muscle physiology as seen in COPD [129]. 
Apoptosis and an impaired regenerative potential of the muscle that is associated 
with a high degree of systemic inflammation have also been implicated as crucial 
factors in the loss of muscle mass and dysfunction as seen in COPD [125]. This is 
important as it helps us understand the inflammatory cascade in COPD better, and 
also provides insight into the potential role of rehabilitation strategies as well as 
novel anti-inflammatory agents (such as TNF-α inhibitors) to help reverse the 
observed muscle dysfunction in this cohort [129]. 
 
Osteoporosis: This is another well-known association with COPD and the 
prevalence of osteoporosis in COPD varies between 4% and 59%, depending on the 
diagnostic methods used, the population studied and severity of the disease [130].  A 
recent systematic review calculated an overall mean prevalence of osteoporosis of 
35% from 14 studies that measured bone mineral density (BMD) in COPD. The 
individuals in these studies had a mean age of 63 and a mean FEV1 per cent 
predicted of 47% [130]. 
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Over half of patients with COPD recruited for the large TORCH (Towards a 
Revolution in COPD Health) trial (6,000 patients) also had osteoporosis or 
osteopenia as determined by DEXA scan [131]. In another cross-sectional study, the 
prevalence of osteoporosis was 75% in patients with severe COPD patients and 
strongly correlated with reduced fat free mass [132]. The other remarkable finding 
from this study was that the prevalence rate was high for males and even higher for 
postmenopausal females. 
 
Studies show that low-grade systemic inflammation, as can be observed in clinically 
stable COPD patients, could be the main underlying mechanism able to explain this 
relationship of low BMD and airflow obstruction in this cohort [133]. It has also 
been shown that using the plasma level of markers like CRP, IL-6 and TNF-α as 
surrogates of systemic inflammation, significantly higher levels of these cytokines 
were observed in the COPD patients who had abnormal BMD [134]. The role of 
low-grade systemic inflammation in COPD in causing this is still deliberated, but 
the significant BMD improvement one year after lung volume reduction surgery in 
severe emphysematous COPD patients, as compared with a similar control group of 
COPD patients treated with pulmonary rehabilitation, further corroborates the fact 
that mechanical derangement of lung structure because of air trapping and 
parenchymal destruction might be pathogenically relevant in sustaining an overall 
chronic inflammatory response and its consequences [134, 135]. 
 
The main determinant of this bone fragility could thus be the chronic inflammation, 
as shown by the interactions between the inflammatory mediators and the bone 
remodelling. The inflammatory disease activity consequently adds to the 
osteoporotic risk factors in these patients and potentially to the overall inflammatory 
burden of the disease [136]. 
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1.5 Need for biomarkers of lung inflammation in COPD 
 
 
COPD is thus a complex, multi-component, heterogeneous chronic inflammatory 
lung disease that has varied clinical, functional and radiological presentation 
amongst patients despite similar degrees of airflow limitation [32, 39]. The standard 
way of assessing COPD in terms of lung function, (e.g., FEV1) by itself does not 
adequately describe the complexity of the disease, and thus cannot be used in 
isolation for optimal assessment and the management of the disease. 
 
As discussed, inflammation has a central role in the pathogenesis of both the lung 
and systemic effects of COPD. Within the airway lumen in COPD, there are 
increased numbers of neutrophils and their activation results in secretion of 
cytotoxins including proteinases such as neutrophil elastase and oxidants [137]. 
 
Studies have also shown an association between airway neutrophil burden and 
disease severity and progression of airflow limitation [138]. 
 
Neutrophil elastase and reactive oxygen species have been shown to up-regulate 
epithelial mucin gene expression with consequent increased mucus production in 
COPD [137]. 
 
Understanding the role these various inflammatory cells play in COPD is difficult 
because of the heterogeneity of the disease. Nevertheless, inflammatory cells, 
including neutrophils and macrophages as well lymphocytes, have indeed been 
implicated in this process as they release proteolytic enzymes and generate oxidants 
which can cause tissue damage, as well as activate cytokines and chemokines, 
potentiating further inflammation and triggering an immune response [139, 140]. 
 
Lymphocytes have also been associated with emphysema severity as well as airflow 
limitation and are found in increased numbers in the sputum of COPD patients and 
may have an important role in the pathogenesis of COPD [141]. The ability to assess 
and monitor the inflammatory response in the lungs in COPD patients is therefore 
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important for understanding the pathogenic mechanisms, but also could provide a 
measure of the activity of the disease as well as provide means to assess the 
potential of the various novel anti-inflammatory therapies. 
 
Also, the fact that 50% of drugs fail in Phase III trials due to lack of demonstrable 
efficacy and that respiratory drugs are often the most costly to develop, highlights 
the need for non-invasive, quantitative molecular biomarkers that guide the selection 




1.5.1 Current ways of assessing lung inflammation 
 
 
The development of novel biomarkers of lung inflammation in COPD is a major 
area of research interest. The traditional ways of assessing lung inflammation 
currently include measuring inflammatory cells and cytokines in sputum, as well as 
measurement of distal airspace inflammation involving bronchoscopy and 
bronchoalveolar lavage (BAL). Some of these techniques, like BAL, are invasive; 
sputum induction requires inhalation of a hypertonic saline, which may provoke 
bronchoconstriction in COPD patients. Furthermore, processing the sputum and 
BAL samples requires approximately 2 hours work by a well-trained person to 
obtain reliable measurements, which limit its use. 
 
Some concerns regarding the viability and reproducibility of the results from these 
samples have also been reported, with erroneous results noted when the analyses 
have not been performed in the first few hours of obtaining the sample [143]. 
Sputum assessment reflects inflammation in the central airways [144], while the 
results of bronchoscopy and BAL vary according to the region of the lungs that is 
sampled [145]. Other non-invasive methods such as exhaled breath measures, 
particularly nitric oxide, carbon monoxide, volatile hydrocarbons and exhaled breath 
condensate, all hold promise as surrogate markers of inflammation in COPD but 
require further validation [146]. There is therefore a need for other validated 
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biomarkers of lung inflammation. 
 
The clinical development of anti-inflammatory therapies for lung diseases is thus, to 
an extent, hampered by the lack of robust methods to measure the anti- 
inflammatory activity of novel agents, necessitating large expensive FEV1 based 
studies. A robust method to measure lung inflammation potentially with validated 
and more reproducible and demonstrable methodologies using relatively non- 
invasive techniques like dynamic PET scanning would indeed enable, in the future, 
to assess better responses to therapeutic interventions in chronic inflammatory lung 
conditions like COPD. 
 
 
1.5.2 18FDG PET/CT scanning as a potential biomarker of lung 
inflammation 
 
External imaging of intravenously injected radio-labelled markers of inflammatory 
processes has the potential to provide a non-invasive and repeatable method of 
monitoring inflammatory cell behaviour, allowing the whole lung to be studied in 
situ. In this context, imaging using 18fluorodeoxyglucose positron emission 
tomography-computed tomography (18FDG PET-CT) holds great promise. Use of 
PET/CT provides images of the concentration of a radiotracer in the body at a 
spatial resolution of approximately 4-7mm and has been used to assess the 
metabolic activity of pulmonary inflammatory cells particularly neutrophilic activity 
[146, 147]. 
 
There is considerable evidence that neutrophils contribute primarily to the increased 
uptake of 18FDG in the lungs and that the FDG-PET signal correlates with the 
presence of activated neutrophils [147]. 
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Mechanism: Following injection 18FDG is transported to the cell by the same 
mechanism as glucose facilitated transport by glucose transporter GLUT-1 (K1). It 
is then phosphorylated by hexokinase to 18F-FDG-6 phosphate (Figure 1.4) and can 
neither undergo further metabolism nor diffuse out of cells. As the 
dephosphorylation (k4) reaction also occurs slowly, FDG-6-phosphate is trapped 
intracellularly and accumulates in proportion to the metabolic rate of the cell [148]. 
Hence 18FDG uptake in the lungs could be potentially used to measure the 
inflammatory activity of the neutrophilic cells in the region of interest. 
 
A series of previous observational studies have suggested that PET CT could be a 
useful tool to assess the neutrophilic inflammatory burden in the lungs in conditions 
like cystic fibrosis, pneumonia, and experimentally-induced lung inflammation [147, 
149, 150]. 
 
The advantages of PET imaging include its relative non-invasiveness, ease of 
quantification, and the ability to assess the entire lung. As it has been shown to 
generate both quantitative and spatial data of pulmonary glucose uptake, 18FDG 
PET-CT may therefore represent a non-invasive, repeatable biomarker of pulmonary 




Figure 1.4: Transport and metabolism of FDG. 
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Static vs dynamic imaging: A single static PET imaging technique is easier in a 
relatively fragile patient but may generate a weaker signal in the context of lung 
inflammation in COPD. The signal from static PET lung imaging is usually 
quantified by measuring the standardised uptake value (SUV). SUV is a simple and 
straightforward index of tracer uptake, but it introduces quantification bias since it  
is neither directly linked to any physiological process nor does it take account of 
blood flow and therefore might not relate to inflammation alone [151]. By contrast, 
dynamic PET studies offer the possibility of full kinetic modelling in real time and 
makes use of the time variable tracer uptake and radiotracer supply, thus   
potentially providing much more robust information on the metabolic activity of the 
tissues [152, 153]. 
 
Dynamic imaging therefore potentially allows a better quantitative description of 
tracer behaviour by taking into account the blood flow and the transportation rate 
constants between the blood and the tissue [154], which is particularly important in 
lung studies. This will be discussed more in detail in the methodology chapter. 
 
 
1.5.3 Previous studies supporting the role of 18FDG PET/CT as a 
potential biomarker of lung inflammation 
 
Some studies in the past have investigated the role of dynamic PET imaging using 
FDG as the surrogate with encouraging results. Parr and colleagues conducted a 
conventional voxel-based, dynamic PET CT image analysis in patients with COPD 
and healthy controls that quantified regional pulmonary uptake of 18F-FDG [152]. 
Plasma 18FDG activity was derived from venous blood sampling, performed at 
intervals during the scan.  Quantification was determined by ratio of lung tissue PET 
signal to plasma radioactivity, basing it on a statistical analysis called the 3- 
dimensional Patlak analysis that will be discussed in detail in the methodology 
chapter. The study showed regional differences in pulmonary 18FDG uptake and, in 
patients with COPD, a correlation between 18F-FDG uptake rate (Ki) and clinical 
measures of disease severity. Uptake in the upper lobe of the lung was greater in 
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patients with COPD compared to the healthy control group and correlated with 
FEV1% (p=0.001). In my study the aim was to test the Patlak analyses and also to 
take this a step further and assess the role of FDG as a radioactive tracer using 
conventional kinetic modelling analyses. This has also been discussed in more detail 
in the methodology chapter. 
 
Harris et al studied pulmonary 18FDG uptake in patients with allergic asthma 
following a segmental allergen challenge, induced by bronchoscopic application of a 
pro-inflammatory substance (allergen extract from cat hair) in one segment of the 
lung [153]. Net 18FDG uptake in this study was again analysed by Patlak method. 
 
Results showed increased tracer uptake in the allergen challenged segment 
consistent with increased inflammation in that segment. The study showed a linear 
relation between the numbers of inflammatory cells in BAL (performed 24 hours 
post challenge) from the allergen-challenged airway and the 18FDG uptake. 
 
Jones and co-workers also showed that Streptococcus pneumoniae-induced 
pneumonia in rabbit lungs, which causes a profound inflammatory response lasting 
several days, produced pronounced FDG uptake 15 hours after the onset of 
inflammation with little uptake by 48 hours [154]. In the same study they also 
studied the bleomycin lung injury model, which progresses from an acute 
inflammatory stage to chronic inflammation, and scarring 18FDG uptake was 
detectable by PET for up to 21 days. These findings are again suggestive of the 
potential role of 18FDG as a biomarker of lung inflammation. The role of 18FDG has 
been investigated in idiopathic pulmonary fibrosis too and the uptake seem to be 
related to the lung density and ways to correct for this play an important role in 
interpreting the results [155]. This will be more extensively discussed in Chapter 4. 
 
Chen et al also studied the role of 18FDG PET imaging as a biomarker of lung 
inflammation in a cohort of patients with cystic fibrosis and healthy volunteers 
[147]. The uptake of [18F] FDG by the lungs was measured as in previous studies as 
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the net influx rate constant Ki obtained from the Patlak analysis. Patients were 
stratified by rate of decline in pulmonary function into stable, intermediate, and 
rapidly declining groups. Ki was compared between the groups and was correlated 
against neutrophil numbers in bronchoalveolar lavage.  The study showed that the Ki 
was significantly elevated (p<0.05) in patients with CF compared with healthy 
control subjects, particularly in patients with rapidly declining pulmonary function, 
suggesting potential relationship with disease activity. Ki also correlated positively 
with the number of neutrophils present in the BAL fluid in this study. 
 
All of these studies therefore provide support for a role for dynamic 18F FDG PET 
pulmonary imaging as a tool to assess the inflammatory burden in patients with 
chronic lung disease; to identify patients with more aggressive inflammatory 
diseases, and may be useful in monitoring changes in inflammation in response to 
novel therapies. However, none of these studies assessed both Patlak analyses and 
conventional compartmental modelling method [155] in the same cohort of study 
subjects. 
 
In the current study, I thus aimed to compare the role of FDG PET as an 
inflammatory biomarker using the compartmental method of analysis as well, which 
is a mathematical framework commonly applied to estimate PET tracer kinetics. A 
compartmental model requires a plasma input, referred to as an input function (IF) 
and contains a series of compartments which each represent a simplified component 
of the radiotracer transport and binding process [155]. This has the potential benefits 
of better correction for the tissue fraction effect [TFE] (correction for the effect of 




1.6 Study hypotheses and aim 
 
 
A protocol for dynamic 18FDG-PET imaging enhanced by co-registering FDG-PET 
with quantitated pulmonary CT, enabling measurement of the extent of emphysema, 
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has thus been used to assess lung inflammation using 18FDG-PET in COPD patients 
[152]. Further validation of this methodology; including assessment of the 
reproducibility technique in COPD patients and then comparing the results with 
some healthy controls, were the main aims of this study. 
 
Hypothesis of this study was thus that combined 18FDG-PET/CT with focus on 
specific lung regions may provide a quantitative, reproducible assessment of lung 
inflammation in COPD patients, capable of detecting changes with future anti- 
inflammatory therapeutic interventions. 
 
Specific aims of the study were as follows: 
 
1. To establish an optimum and validated local protocol for focused 18F FDG- 
PET/CT imaging of lung inflammation in COPD patients. 
2. To study reproducibility of 18FDG-PET/CT in this cohort. 
 
3. To relate 18FDG-PET imaging with lung structure (assessed as emphysema by 
CT scanning) and to lung inflammation. 
4. To compare various methodologies of PET CT scan to measure lung 
inflammation (static vs dynamic scan including Patlak analyses and 
compartmental modelling technique). 
5. To compare 18FDG-PET/CT imaging between the COPD cohort and age 
matched healthy volunteers. 
























2.1 Overview of methodology 
 
 
This was a single centre, open label exploratory study to investigate the role of 
dynamic FDG PET scanning technique as a potential non-invasive biomarker of 
lung inflammation in COPD patients. 
 
The study was divided into three phases: 
 
 
Feasibility phase: To develop a protocol for dynamic FDG PET scanning and to 
assess different modes of analysis. In this phase six stable COPD patients with mild 
to moderate airflow limitations underwent FDG PET scanning. 
 
Reproducibility phase: This was to test the reproducibility of the methodology 
over time. In this phase of the study 20 COPD patients were scanned twice 4 weeks 
apart. These patients were divided into groups of ex-smokers (n=15) and current 
smokers (n=5 patients) to compare potential differences in the inflammatory signals 
between these two subgroups in addition to assessing reproducibility. 
 
Comparative phase: In the final phase I scanned 5 healthy controls (non-smokers 
with normal PFTs) and compared the results with those of the COPD patients. 
 
Figure 2.1 summarises the experimental plan of these three phases. 
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Figure 2.1: Experimental plan of the study. 
 
 
2.2 Recruitment of participants 
 
 
Recruitment source: The patients were mainly recruited from the respiratory 
outpatient clinics and in-patients of the Royal Infirmary of Edinburgh (RIE). Some 
patients were also recruited from primary care through the Scottish Primary 
Research Network (SPCRN). 
 
An invitation with information about the study was sent out to all potentially eligible 
patients. An 'expression of interest' form was also provided with a stamped 
addressed envelope so that interested patients could respond to the research team 
with their contact details. Unless the patient had been seen in the hospital clinic very 
recently, the patient's CHI number was used on the NHS database to check that the 
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patient had no major medical or social reasons why it would be inappropriate to 
send an invitation. 
 
When primary care patients were recruited, GPs were asked to send out a postal 
invitation to patients on their COPD register, enclosing information about the study 
and the 'expression of interest' form to be returned to the research team. 
 
Consenting Process: Potential participants received a letter of invitation from their 
clinician (the consultant or GP as appropriate), enclosing an information sheet to 
enable them to decide if they would be interested in participating. If they wished to 
express interest they were asked to complete the 'expression of interest' form, which 
included basic demographic information (age, gender) and their preferred contact 
details. The completed from was returned to the clinical research fellow who 
contacted the patient, answered any questions and, if the patient was still interested, 
an appointment was arranged for a clinical assessment. Informed consent was 
obtained after the potential participants read the detailed study information booklet 
and discussed any questions in person. 
 
 
2.3 Study outline 
 
 
2.3.1 Combined 18F FDG PET/CT protocol development (Feasibility 
Phase) phase 
 
The following were the objectives for this phase of the study: 
 
 To test if a previously developed protocol for combined 18F FDG PET/ CT 
dynamic imaging could be validated in the COPD cohort [154]. 
 To compare different input functions (venous blood vs. arterial blood sampling 
vs. image derived techniques), to determine whether or not an arterial input 
function derived from the dynamic PET images is comparable to the blood 
derived methods [156]. 
 To analyse if 18FDG kinetics in the lungs using the Patlak analysis method, 
43  
and more complex kinetic models in the COPD cohort, could be used as 
markers of lung inflammation [157]. 
 To use simultaneous acquisition of CT with FDG-PET to enable co-
registration of PET with CT images, which would allow quantification of 
emphysema to potentially increase the sensitivity of the PET signal [158]. 
 
 
2.3.2 Reproducibility and comparative phase 
 
 
 The reproducibility of the measurements made on dynamic FDG PET 
scanning were assessed by scanning 20 stable COPD patients on two 
occasions twice 4 weeks apart. 
 The reproducibility phase compared the various parameters obtained from 
analysis of dynamic FDG PET lung scanning (Patlak analyses and 
compartmental modelling analysis) to determine comparable results were 
obtained or not between the two visits of COPD patients. 
 The comparative phase related the results obtained from analysis of dynamic 





 Twenty clinically stable COPD patients with moderate-severe disease using a 
spirometric classification (FEV1 30-79% predicted, post bronchodilator 
FEV1/FVC ratio <0.7) were studied. 
 18FDG PET/ CT scan was repeated on the same study cohort after 4 weeks. 
 Patients were assessed and examined clinically together with measurements of 
FEV1 to ensure clinical stability. 
 Induced sputum (when possible) and blood sampling was carried out using 
standardized protocols. Sputum and blood samples were processed for 
differential cell counts and sputum supernatant and serum used in the analysis 
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of inflammatory markers. 
 Concentrations of sputum inflammatory biomarkers IL-6, IL-8, eosinophil 
cationic protein, and alpha-2-macroglobulin were measured in sputum using 
validated ELISA assays (Abcam Inc, Cambridge UK). 
 In the serum, concentrations of the cytokines IL-6, IL-8 (Abcam Inc.) and 
Fibrinogen and high sensitivity CRP were determined using standard ELISA 
laboratory assays. 
 
2.3.3 Safety monitoring of patients 
 
 
• Patients were observed for 2 hours post scanning to monitor for any clinical 
side-effects. A check phone call was made on the day following the scan to 
ensure the patient's wellbeing. 
• Any incidental findings on the scan were reported to the patient and the GP 
and appropriate referral to specialties made if needed. 
 
2.3.4 Dose calculation and risk assessment 
 
 
A total dose of 14 milisieverts (mSv) (feasibility phase) or 28 mSv (reproducibility 
phase) was used in this study. 
 
The estimated associated risk of developing fatal cancer is proportional to dose. 
Using a risk of 5% per  Sv in  a healthy adult  population,  the  estimated associated 
risk of developing fatal cancer as a result of this exposure is in the region 1 in 700 (1  
in 1400*).  These risks were therefore classified as low. This assessment was 
performed with the assistance of Dr Alison Fletcher, Principal Medical Physicist, 
based at the Royal Infirmary of Edinburgh (alison.fletcher@ed.ac.uk). 
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*Denotes the dose for the feasibility phase of the study as these patients were only 
scanned once. 
 






Chemical Form FDG 
Activity  200MBq 
Route IV 
Administrations1 1 




1. Number in parentheses indicates number of administrations for subjects in protocol development part of study 
2. ARSAC Notes for Guidance 2006 Appendix V11 
 
Procedure No of procedures4 Estimated procedure 
dose (mSv)1,2 
High-resolution Chest CT on 
inspiration 
 
1 5 mSv 
High-resolution Chest CT on 
expiration 
1 2 mSv 
CT attenuation correction scan 
for dynamic lung PET3 
1  3 mSv 
 
1Using ICRP103 tissue weighting factors and scanner-specific DLP to effective dose conversion factor 
2Dose for a standard sized patient based on phantom measurements. 
3Modified protocol with fixed tube current (effective mAs 63, CTDIvol 4.2 mGy) 





2.3.5 Patient characterisation 
 
 
Inclusion criterion for COPD patients: 
 
• Stable COPD patients with moderate to severe air flow limitation FEV1 30-
79% predicted with a post bronchodilator (2.5 mg of nebulised salbutamol) 
FEV1/FVC ratio <0.7. 
• Smoking status: ex-smokers (n=5 in the feasibility phase and n=15 in the 




In order to study COPD patients who were most likely to have chronic lung 
inflammation I included: 
• Patients who had at least one exacerbation of COPD in the preceding 12 
months prior to the study recruitment. 
• Patients with symptoms of chronic bronchitis, defined by the MRC criteria 




• Post-bronchodilator FEV1 <30% of predicted value.  (We excluded these very 
severe COPD patients as we anticipated they would find it difficult to lie flat 
on the scanner for an hour, potentially therefore adding to the burden of 
movement artefacts.) 
• Age <35 or >85 years. 
• History of previous lung transplant. 
• Any lung surgery within the past 2 years. 
• On any thoracic surgery waiting list. 
• Severe concomitant disease (e.g., serious malignant disease, congestive heart 
failure, NYHA III/IV, clinical significant pulmonary fibrosis, life expectancy 
<2 years). 
• Women of childbearing age not on any long-term contraception. 
• Pregnant or lactating women. 
• Participation in another clinical treatment trial within 30 days prior to 
inclusion at baseline. 
• Subjects who have previously had 3 or more CT scans. 
• History of diabetes. 




Definition of clinical stability: 
To ensure that the study patients were all clinically stable at the time of study: 
• Patients had no exacerbation in the 4 weeks prior to commencing the study. 
• No exacerbations in 4 weeks between the two visits for the reproducibility 
phase. If an exacerbation occurred during this period, the second scan was 
postponed for a 4-week exacerbation-free period. 
• Spirometric stability between the 2 visits in the reproducibility phase with a 
post-bronchodilator FEV1 variability was ensured with a variation of less than 
200ml over the 2 weeks prior to the first scan (consenting visit) and between 
the day of the first scan and on the day of the second scan.  This was achieved 
on all patients. The 200 ml cut-off was decided based on a previous study 
[152].   
• For the feasibility study, post-bronchodilator spirometry was assessed on the 
screening visit day and the day of the scan, and the scan was performed if 
variability in FEV1 between each measurement was less than 200ml. 
 
Healthy controls: All healthy subjects were between 40-65 years of age, no 
previous history of any medical illnesses and were non-smokers with normal 
pulmonary function tests. 
 
2.3.6 Patient preparation on the scan day  
 
The following measures were followed for every COPD patient scanned in this 
study. Steps:
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1) Medications: All patients were receiving inhaled corticosteroids and long-
acting bronchodilator(s). Patients were allowed to take their inhalers as per their 
normal schedule, other than withholding the ICS on the morning of the scan.  All 
patients were given 2 puffs of their inhaled short-acting beta agonist inhaler 10 
minutes prior to the scan. Other medications were allowed as per normal. 
2) Patients were fasted from midnight the previous day prior to the scan. 
3) A large bore cannula intravenous was inserted into an arm vein, flushed with 
0.9% saline and used for FDG injection. 
4) Another venous (at least 18 gauge) cannula was inserted into the patient's 
other arm. A 3-way tap with 15 cm tubing was then attached. A drop of blood was 
withdrawn and used to perform the first (baseline) blood glucose measurement. The 
cannula and tubing was then flushed with 0.9% sterile saline. 
5) The aim was to keep the blood sugar level between 4-10 mmol/L prior to 
commencing the scan, since high blood sugar levels can compete with the FDG 
cellular uptake potentially giving false negative results. 
6) All subjects were scanned supine. 
7) Subjects were assessed for haemodynamic stability prior to the scan by 
recording blood pressure, heart rate, temperature and oxygen saturation (on room 
air). 
8) An arterial cannula was inserted into the radial artery in the non-dominant arm 
under local anaesthetic (5ml of 2% lignocaine) using an aseptic technique to obtain 
the arterial blood samples. This was applied only to the first 6 patients as a part of 
the feasibility study. 
 




2.4 Protocols for PET/CT Analysis 
 
 
2.4.1 CT protocol and analyses 
 
 
CT is an anatomical imaging method, which makes use of a rotating X-ray source to 
build a 3D image. This is attained through multiple quantification of attenuation 
through a plane of the body with finite thickness to attain attenuation values, which 
are then converted to produce images in terms of CT-numbers known as Hounsfield 
Units (HU) [160]. 
 
All subjects in this study were scanned using a Siemens Biograph CT, (Siemens 
Medical Systems, Erlangen, Germany).  A full inspiratory CT scan was performed 
initially prior to commencing the dynamic PET scanning, followed by a full 
expiratory scan (only on visit 1). 
 
Reconstruction parameters were used as per the COPDGene study [161]. This was 
then followed by an attenuation correction CT (ACCT) scan (relaxed expiration 
phase) which was matched to the PET bed. The full inspiration HRCT and whole 
lung relaxed expiration CT was registered to ACCT, matched to PET using 
advanced normalization tools (ANTS) [http://www.picsl.upenn.edu/ANTS/], and 
lung regions transferred to PET using the same transformations. 
 
Analysis of full inspiration and expiration CT of whole lung were done using Vida 
Apollo software (Vida Diagnostics, Coralville, USA), as used by COPDGene Study 
as well, to generate lobar regions of interest [161]. 
 
Need for attenuation correction scan (ACCT): The body attenuates the majority of 
the emitted photons, and attenuation correction (AC) is therefore essential for 
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accurate quantification of the emitted signal. Attenuation correction is thus intended 
and imperative for use in a single scanner that combines volume-imaging (3D) PET 
with x-ray computed tomography (CT) for the purpose of providing accurately 
registered anatomical localization of structures seen in the PET image. 
 
Reconstruction details for the CT scans were as follows: 
 
 
For the inspiratory CT scan: 64x0.6mm collimation, 120 kV, 125 effective mAs, 
pitch 1.1, 0.75mm thickness, 0.5mm slice interval, rotation time 0.5 s, B31f and 
B46f reconstruction filters were used. 
 
For the expiratory CT scan: 64x0.6mm collimation, 120 kV, 31 effective mAs, 
pitch 1.1, 0.75mm thickness, 0.5mm slice interval, rotation time 0.5 s, B31f and 
B46f reconstruction filters were used. 
 
For the ACCT: 64x0.6mm collimation, 120 kV, 63 effective mAs, pitch 1.1-rotation 
time 0.5s. For lung analysis recons: 0.75mm thickness, 0.5mm slice interval, B31f 
and B46f reconstruction filters were used. For attenuation correction recon: 780mm 
FOV, 5mm thickness, 3mm slice interval, B19f filters were used. 
 
Slides were reconstructed at 3mm and 1.5mm slice separation (with use of Vida 
Apollo software) to analyze the attenuation correction CT. 
 
Correction for BMI was applied as follows: Relative scaling of effective mAs 
setting to correct for BMI was used, ie: 
BMI<20: Inspiration 90 eff mAs, expiration 23 eff mAs, and attenuation correction 
eff 45 mAs 
BMI 20-30: Inspiration 125 eff mAs, expiration 31 eff mAs and attenuation 
correction eff 63 mAs 
BMI>30: Inspiration 175 eff mAs, expiration 44 eff mAs, and attenuation correction 
eff 88 mAs 
Quantification of emphysema was measured on the full inspiratory by measuring 
the % of low attenuation areas (voxels) with Hounsfield units (HU) <-950 HU 
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investigated by the following procedure (figures 2.2 a-c): 
 Areas of emphysema were transferred from HRCT full inspiration using the 
lung mask technique, defined by areas below -950 HU [160, 162]. 
 Non-rigid registration of HRCT full inspiration to attenuation-correction CT 
(at defined level of inspiration) with lung mask defined in attenuation-
correction CT using Elastix software (http://elastix.isi.uu.nl) which was also 
used for similar registration in lung lobar analysis). Emphysema masks were 
transferred using the same registration parameters 
 To investigate if removal of emphysema had an effect on the PET signal, I 
used a protocol for removing emphysema in lung voxels of interest (VOIs) 
containing tissue with Hounsfield Unit below -950 HU on the full inspiration 
CT (corresponding to the relative area -950 [RA -950] standard) and 
subsequently non-rigidly transforming these volumes of interest (VOI) to 





Figure 2.2a: shows an example 
of a severe COPD patient with 
defined areas of emphysema 
according to lobes using VIDA 
software, the spheres are used 
in VIDA to represent the size of 
contiguous areas below -950 
HU in a 3D display with the 




Figure 2.2b: is a CT image of a COPD patient showing emphysema areas 
below -950 HU in full inspiration. 
 
Figure 2.2c: shows an example of a FDG time activity curves after removal of 
areas of emphysema in a COPD patient. 
 
 
2.4.2 PET protocol and analyses 
 
 
PET is a technique that utilises molecules labelled with positron emitting 
radionuclides (radiotracers like 18F FDG) to image physiological and molecular 
function. The main advantage of combining this with CT scan lies in the fact it 
allows determination of both anatomical and functional information in one clinical 




In my study, the PET data was captured with the patient in free breathing during 60-
minutes acquisition, and was therefore assessed at an average level of 
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inspiration. It was assumed that the ACCT at relaxed expiration matches the average 
PET. The full inspiration CT was registered to 1mm slice thickness relaxed 
expiration ACCT covering the full lung using non-rigid transformations (ANTS, 
PICSL, UPenn), and then full lung 1mm slice thickness ACCT was registered 
rigidly to 3mm ACCT matched to the full range of PET. Volumes of interest (VOIs) 
for lungs and lobes were segmented in the full inspiration HRCT and whole lung 
relaxed expiration ACCT using Apollo software (Vida Diagnostics, Coralville, 
USA), and transferred to PET using the previously calculated transformations. 
VOIs were further processed by morphological erosion to reduce interference from 
the myocardium and liver (Figure 2.3). 
 
 
Figure 2.3: A single frame from dynamic PET acquisition showing lung lobes 
outlined with morphological erosion from the myocardium. 
 
 
PET imaging protocol: During each study experiment, the following sequence was 
followed: 
1. Confirm availability of ligand and PET scanner. 
2. Ensure subject is accurately briefed, is happy to proceed and has had the 
opportunity to pass urine. 
3. Obtain reliable venous and radial arterial access (venous access first) whilst 
the subject is in the scan room and do so only after first ensuring that the equipment 
and ligand are functional and available. 
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4. Position subject in the scanning position and ensure they are comfortable. 
5. Remove three-way tap with extension from art-line and attach PTFE tubing. 
6. Baseline blood sample (aspirate until pure blood, take sample and then flush 
with heparinized saline. 
7. Attenuation correction CT (one PET 'bed' coverage 22cm positioned over 
lungs). 
When all team in place: 
8. Start PET and inject 200MBq FDG 2 seconds after PET start, as a fast bolus. 
9. Start 60-minute PET LM acquisition simultaneously with injection. 
10. Blood samples at time points 0, 1.5, 3, 5, 7, 10, 12.5, 15, 20, 25, 30, 40, 50, 60 
minutes). The arterial samples (only during the feasibility phase) were also taken at 
the same time points. 
11. End of scan. 
12. Specimens transported to nuclear medicine for whole blood count, 
centrifugation and plasma count. 
13. Dispose of consumables appropriately. 
14. Following the scan, subject was observed for 2 hours and if stable was 
discharged home later that day. 
 
Measurement of [18F] FDG activity in whole blood and plasma: Whole blood and 
plasma radioactivity were measured for each blood sample using a Packard Cobra   
II Auto-Gamma counting system (GMI Inc., Ramsey, MN, USA). The radioactivity 
of each aliquot of whole blood was counted over 1 minute. The blood samples were 
then centrifuged (300g, 20°C, for 10 minutes) and the plasma extracted into 
separate, labelled tubes. The radioactivity of each aliquot of plasma was counted 
over 1 minute. The radioactivity counts for whole blood and plasma samples were 
then individually corrected for sample weight, background radioactivity  (calculated 
from an empty control tube) and decay time to give decay-corrected whole blood or 
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plasma activity (Bq/ml). 
 
For each subject, the 18FDG activity in lung tissue and in plasma was used to 
generate time-activity curves and calculate influx constant (Ki) as described below. 
 
 
2.5 Methods for analyses of pulmonary uptake of FDG from 
combined PET/CT data 
 
Pulmonary uptake of FDG was quantified using the following methods: 
 
 
1. Patlak analyses: Arterial input functions (AIFs) were derived from either 
blood samples or image-derived from the lumen of the aortic arch or descending 
aorta (Figure 2.4). Patlak compartmental analysis [157] was performed on these 
input functions. Estimates of Patlak slope (influx constant Ki) and intercept (initial 
volume of distribution) were calculated from the time-activity curves for the 
volumes of interest (VOIs) previously segmented and registered to PET using 
PMOD (PMOD Technologies Ltd, Zurich, Switzerland) [163]. This is explained in 
detail in section 2.5.1. 
 
2. Kinetic modelling analyses: The kinetics of 18F-FDG uptakes in the lungs 
were also analysed with the conventional standard compartmental modelling 
method. This is explained more in detail in section 2.5.2. 
 
3. Standard uptake value (SUV) analysis using data acquired between 50-60 
minutes post-injection. This is explained in detail in section 2.5.3. 
 
2.5.1 Patlak analyses 
 
 
In quantitative dynamic PET studies, compartment modelling with a plasma input is 
usually considered as the standard approach for a full analysis of tracer kinetics. A 
compartmental model is usually described by a number of differential equations and 
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parameters for tracer kinetics in vivo [155]. The parameters of a compartmental 
model are commonly estimated by fitting the measured plasma input to the 
measured tissue time activity curves (TACs) using nonlinear or linear regression. 
The selection of a specific compartment model requires knowledge of the in vivo 
tracer and the biochemical and physiological attributes of the model evaluated. By 
focusing on the macro-parameters of tracer kinetics, such as uptake rate constant and 
total distribution volume, the laborious and complicated procedure of the classical 
compartmental modelling technique can be remarkably simplified by graphical 
analysis methods such as using the Patlak analysis technique. 
 
Patlak analysis is a series of 3 dimensional graphical analyses where the radioactive 
tracer undergoes a transformation and is then plotted against normalised time [157]. 
It is therefore a graphical analysis technique based on the principle of a 
compartment model that uses linear regression to identify and analyze 
pharmacokinetics of tracers with irreversible uptake, as is in the case with FDG. 
 
The method is less model-dependent because it does not depend on any specific 
configuration for the tracer, the minimal assumption being that the behaviour of the 
tracer can be approximated by the same concept as the two-compartment modelling 
hypothesis – a "central" (or reversible) compartment that is in rapid equilibrium with 
plasma, and a "peripheral" (or irreversible) compartment where tracer enters without 
ever leaving during the time of the measurements. 
 
 
This graphical tool therefore analyses the uptake of a radioactive tracer in a two- 
compartmental model, with plasma representing the reversible compartment 
(Figure 2.4). Upon cellular uptake (for example, within the lungs), 18F FDG becomes 
phosphorylated by hexokinase and is irreversibly trapped. After sufficient time has 
elapsed to create equilibrium between the two compartments, the curve of the Patlak 
plot becomes linear, where the slope is equivalent to Ki (uptake rate constant) and 
the ordinate intercept indicates the distribution volume. 
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The Patlak analysis thus depends on some assumptions, including equilibrium being 
achieved between the blood and tissue compartments and complete entrapment of 
the tracer without loss (in the case of FDG, by de-phosphorylation) from the tissue 




Figure 2.4: showing a graphical representation of Patlak analyses. 
 
 
The Patlak 2-tissue compartment method therefore is an irreversible model of FDG 
activity in lung that is corrected by FDG activity in blood plasma to give an influx 
constant (Slope). 
 
Figure 2.4 shows a typical example where: 
Y-axis is FDG activity in ROI normalised to plasma activity. 
X-axis is integral of plasma activity in time normalised to plasma activity. 
Net uptake rate of FDG in tissue under study is the slope of straight portion of the 
curve. 
58  





Where t represents time after tracer injection, R(t) is the amount of tracer in 
region of interest, Cp(t) is the concentration of tracer in plasma or blood, K is 
the clearance determining the rate of entry into the peripheral (irreversible) 
compartment, and V0 the initial volume of distribution of the tracer in the 
central compartment, also known as the intercept. The 
first term of the right-hand side represents tracer in the peripheral 
compartment, and the second term tracer in the central compartment. 
 




This means that the measured PET activity is divided by plasma activity, and plotted 
against a "normalized time" (integral of input curve from injection divided by 
instantaneous plasma activity). For systems with irreversible compartments this plot 
will result in a straight line after sufficient equilibration time. 
 
Patlak analysis is thus only applied to timepoints where equilibrium has been 
reached and is therefore less accurate than using the appropriate compartmental 
model to analyse the complete time activity curves. However, where the correct 
model is uncertain, the Patlak model can be exploited as it has the advantage of 
being model-independent as well as fast, less sensitive to noise, and has the ability 
to produce parametric images (parameter estimates on a voxel basis) [163]. 
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In my study the Patlak analysis was performed using arterial input functions (AIFs) 
derived from either venous or arterial blood samples (only during the feasibility 
phase) as well as image-derived modality. As a part of the feasibility phase time, 
activity curves derived from all 3 modalities (image derived/arterial as well as 
venous sampling methods) were compared. An image derived AIF was obtained by 
placing regions of interest (ROIs) on vascular structures in dynamic PET images 
(drawn over the lumen of blood vessels [eg, the aortic arch or descending aorta]), 
and thus exclude the need for manual blood sampling. This method has been 




2.5.2 Compartment kinetic modelling analyses 
 
 
The kinetics of 18F-FDG uptake in the lungs were also analysed using the 
conventional standard compartmental modelling method. 
 
Need for compartmental analyses: In the lung, the average size of an alveolus is 
approximately 0.008mm3, 6000 times smaller than the typical PET voxel [163, 165]. 
Consequently, a single voxel will contain air and multiple tissue components 
including blood and parenchyma. The 18F-FDG signal within each PET voxel or 
predefined region of interest (ROI) in the lungs represents the contribution of 
activity in parenchymal (ie alveolar), airway wall, vascular wall (e.g. endothelial 
cells) and immune cells, as well as blood, and water (i.e. extracellular fluid). A 
number of factors can degrade the lung cells' signal within each voxel, including 
normal respiratory motion and the presence of air that causes partial volume 
averaging within each voxel. Furthermore, the contribution of a signal from 
compartments without specific binding, such as blood or water in the lungs, further 
reduces the signal specificity [155]. The voxel value will therefore then be an 
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average of the tracer concentrations within that voxel and not the signal from the 
parenchyma alone. 
 
A majority of the lung parenchyma is also blood and therefore correcting for this 
blood volume fraction should be important [155]. One such study by Holman and 
colleagues included the blood component and also investigated the effect of air 
content in the lung that influences reconstructed image values the so called 'tissue 
fraction effect' (TFE) in dynamic imaging [155]. 
 
Different approaches have therefore applied to reduce the contribution of 
background 18F-FDG signal from blood and water as well as reduce partial volume 
averaging from air in the ROI so that the lung cell signal can be specifically 
quantified. Kinetic modelling of dynamic PET data can thus help determine the 
fractional blood volume, (Vb) and CT images have been used to estimate the 
regional air fraction (Va). Using these fractional volumes, the 18F-FDG uptake in 
everything that is not air and blood (ie lung cells and water), can therefore be 
measured. 
 
Accurate estimation of tissue density is also essential for accurate attenuation 
correction of PET images and any spatial mis-registration of the measured 
attenuation map and PET activity distribution will result in artefacts [142]. 
Additionally, increased density alone, whether due to pathologic processes 
(infection, malignancy etc) or increased physiological atelectasis at end-expiration 
or denser lungs as potentially observed in healthy individuals, can lead to an 
increase in the observed 18F-FDG signal within a PET voxel. Therefore, changes in 
lung density related to normal respiration can not only lead to large attenuation 
correction errors, but can also introduce additional variability to serial measurements 
over time and limit accurate assessment of the entire lung volume. Since the 
molecular processes of interest are generally within the lung tissue, accounting for 
the underlying causes of density variations within the lung have been used to obtain 
more accurate measures of 18F-FDG uptake, specifically in the lung tissue. 
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Analyses Technique: As another form of analysis to correct for this blood volume 
fraction and air fraction effect, the compartment model analyses were explored. This 
is important as blood volume (Vb) is a large component of the lung voxel (~20%) 
and adds to the PET signal [166]. It affects voxel concentration of the tracer and 
must therefore be taken into account. This is thus important as it gives an 
opportunity to investigate any potential errors if the air and blood components of the 
TFE are not accounted for, as can happen in Patlak analysis. 
 
The Sokoloff method for quantifying 18F-FDG uptakes has served as the basis from 
which all currently used kinetic quantification approaches are derived (142, 163, 
167, 168). Figure 2.5 illustrates the three-compartment model and its associated 
equation. The method was originally developed to measure brain glucose 
metabolism, and one of the key underlying assumptions was that the blood volume 
was small enough that it contributed a negligible signal compared to the brain 
parenchyma. This was recognized as a limitation for applying the method for brain 
tumours, which contain much higher relative blood volumes than normal brain, 
necessitating the addition of a blood volume component to the model [169]. This is 
even more important in the lungs than the brain because the lung is a significantly 
more vascular organ where Vb has been reported at approximately 0.16 and the air 
fraction of approximately 0.74, implying that the blood activity contributes 
substantially to the overall signal. 
 
Figure 2.5: Explains the kinetics of the 2-compartment model: A conventional 
standard compartmental model using nonlinear regression [170, 171], where K1 is 
the forward rate constant (influx) between the blood and tissue compartment, k2 is 









rate constant representing trapping of 18F-FDG intracellularly after phosphorylation 




The typical interpretation is that C1 represents free and non-specifically bound 
tracer in tissue (non-displaceable compartment), and C2 represents specifically 
bound tracer. 
 
The Sokoloff Equation is expressed as follows: 
CM(t)=VACA(t) +VBCB(t) + (1-VB-VA)Cr(t) 
where CM(t) is the measured radioactivity concentration, CB(t) is the radioactivity 
concentration in blood, Cr(t) is the radioactivity concentration in tissue, CA(t) is the 
radioactivity concentration in air, VA is the fraction of air in the region of interest 
(ROI) and VB is the fraction of blood in the ROI. For radiotracers administered 
intravenously like 18F-FDG, the radioactivity concentration in air (CA(t)) can be 
considered negligible in an organ like brain and so the first term of the above 
equation is zero. Nevertheless, the volume of air is still present in the equation as a 
weighting factor of the radioactivity concentration in tissue, when the ROI is in an 
organ like the lungs. 
 
The Patlak analysis, as mentioned previously, has been developed for systems with 
irreversible trapping (where k4 equals to zero). The k4 is assumed to be zero as it is 
presumed that dephosphorylation in the lungs is negligible over the one-hour 
scanning period. 
 
The Patlak parameters in terms of 2 compartment rate constants therefore can be 
summarised as: 
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Slope Ki = k1*k3/(k2+k3) 
Intercept = k1*k2/((k2+k3)*(k2+k3)) 
The Patlak graphical analysis is derived from the general compartment model for 
tracers that are irreversibly trapped in the target tissue. A prerequisite thus for the 
use of a Patlak plot is an irreversible trapping compartment of the tracer, as in the 
case of FDG [142]. 
 
The slope (Ki) and the intercept (Vo) can be interpreted according to the underlying 
compartment model theory with the assumption that FDG is a two-tissue 
compartment irreversible model. The slope thus equals K1*k3/ (k2+k3) (in terms of 
the microparameters of the equivalent two tissue compartment model) and 
represents the influx, while the intercept (Vo) is equivalent to the distribution 
volume and equals k1*k2/ ((k2+k3)*(k2+k3)). These are summarised in the 







Indices used in the kinetic model analysis in my study: 
To correct for the air volume fraction (Va) derived from CT density and the blood 
volume fraction (Vb), two methods have been used in my study to calculate influx 
rate parameter Ki and they are [155]: 
 
1. Retrospective correction of Ki [=K1*k3/ (K2+k3)] using (1-Vb)/ (1-Va-
Vb) [Method 1]. This generated the parameters, KiAoVb and KiPulmVb = Ki data 
from aorta (KiAoVb) and pulmonary artery (KiPulmVb). 
2. Direct estimation of Ki and Vb (Cv = VbCb+(1-Vb-Va)Cpa[K1,k2,k3] ) 
[Method 2]. This generated the following parameters:  KiAoVbVa and 
KiPulmVbVa:  Ki data from aorta (KiAoVbVa) and pulmonary artery 
(KiPulmVbVa). 
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Method 1 could be implemented using PMOD or MIAKAT software, but Method 2 
requires custom modifications to open source software such as MIAKAT (Imanova) 
validated with simulated data [171]. 
 
This will all be discussed further in the results and discussion chapters. 
 
 
2.5.3 Standardised uptake value (SUV) 
 
 
This is the static way of measuring lung inflammation using PET methodology. 
 
 
The standardised uptake value (SUV) is the concentration measured within a region 
or voxel normalized to the patient’s weight and the injected activity and thus will 
reflect the contribution of all components of the lungs (lung cells, blood, and water). 
This is the most common parameter measured clinically for PET assessment due to 
its simplicity, despite its dependency on metabolism in other organs, body mass and 
other confounding factors [172]. 
 
SUV is therefore a semi-quantitative ratio of tissue radioactivity (18F FDG uptake) 
within the region of interest to the injected tracer activity, adjusted for lean body 
weight and the dose of the FDG injected [173]. 




SUV (t) = 
 
c(t) 




where c is the tissue radioactivity concentration (eg in MBq/kg = kBq/g) at time 
point t. 
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The use of SUVs as a measurement of relative tissue/organ uptake facilitates 
comparisons between patients, and has been suggested as a basis for diagnosis. 
However, measured SUVs may have a large degree of variability due to physical 
and biological sources of error, as well as inconsistent and non-optimized image 
acquisition, processing and analysis [173]. 
 
For this study the mean standardised uptake values (SUVs) were calculated from the 
PET images obtained during the final 10-minute frame from regions of interest in 
the lung parenchyma as delineated using the PMOD software. The SUV was 
measured as the maximum pixel signal within the ROI, which is termed the 
maximum SUV [SUVmax] [174]. SUVmax has several attractive features, including 
the fact that it reflects the most metabolically active, and possibly most clinically 
significant, part of the ROI. 
 
The SUV measurement is still a semi-quantitative way of measuring FDG activity 
and may give variable results depending on the following factors: 
• Scatter correction 
• Respiratory motion 
• Partial volume effect 
• Tomographic reconstruction (noise, spatial resolution in the reconstructed 
images) 
• Measurement method 
• Post-injection PET scan time 
• Attenuation correction 
 
 









2.6 Measurement of vascular inflammation 
 
 
The association between COPD and cardiovascular disease, as discussed before, 
results in a poorer clinical outcome in COPD patients, and is believed to be 
mediated; at least to an extent through vascular inflammation [92]. As a sub-study I 
therefore also aimed to quantify vascular inflammation in the COPD patients and the 
healthy controls using combined 18F-FDG PET/CT scan technique. 
 
For this sub-analysis I hypothesised that COPD patients would have increased 
inflammation in systemic arterial walls. 
 
The aims of this sub-study were therefore: 
1. To compare aortic inflammation in ex-smokers with moderate or severe 
COPD, versus healthy individuals using static reconstructions of dynamically 
acquired 18F- FDG PET/CT scans. 
2. To determine the relationship between aortic and systemic inflammation. 
 
 
Indices measured: To quantify vascular inflammation in the COPD cohort, the PET 
signal from regions of interests (ROIs) drawn around the aorta and the mean and 
maximum aortic standardised uptake values (SUVs) were obtained from the pixel 
activity within each ROIs at 50-60 minute scan time period. Three ROIs were drawn 
in this study for each subject in the ascending, descending and the arch of the aorta. 
The mean SUV values obtained were also divided by the mean SUV in the superior 
vena cava (SVC) to obtain a blood-corrected arterial SUV, also known as target-to- 
background ratio [Figure 2.6] (TBR) [175]. These were the two indices that I used 




Figure 2.6: shows circular ROIs on the ascending aorta, descending aorta and 
the superior vena cava (SVC). This technique is standardised and utilised on 
every 3mm slices of trans-axial PET/CT images. 
 
 
2.7 Measurement of systemic markers of inflammation 
 
 
To assess systemic inflammation, I measured the following inflammatory markers: 
Blood: White cell count, fibrinogen, C Reactive protein (CRP) (by conventional 
ELISA techniques). 
 
I also assessed the following cytokines from stored serum samples in COPD and the 
healthy controls: Interleukin 6 (IL6), Interleukin 8 (IL8), Alpha 2 macroglobulin 
(A2MG) and myeloperoxidase (MPO). Standard enzyme-linked immune sorbent 
assay (ELISA) techniques were used to assess the cytokines. The principle of the 




Induced sputum from the COPD patients who could produce a sample were also 
analysed to assess the above cytokines as a measure of airway inflammation. The 
technique followed to process the induced sputum has also been added as a 
supplement in the Appendix section. 
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2.8 Statistical analyses 
 
 
All data were expressed as mean±SEM (standard error of the mean). Normality was 
tested using Shapiro Wilk and Kolmogorov Smirnov tests. 
 
Comparisons between COPD and controls were performed using student t test or 
wilcoxon signed-rank test for non-normally distributed variables. 
Comparison between COPD smokers, COPD ex-smokers and controls were 
conducted using ANOVA with Student-Newman–Keuls as a post hoc test or the 
Kruskall–Wallis equivalent with Dunn's test as a post hoc test for non-normally 
distributed variables. 
 
Correlations were calculated as Pearson's correlation coefficient or Spearman's 
correlation coefficient for non-normally distributed variables. 
 
Analyses were conducted using the SAS Version 9.3 (SAS Institute Inc, Cary, NC, 
USA). 
 
The histograms were drawn using Graphpad Prism (www.graphpad.com). 
 
 
2.9 Power calculation 
 
 
One of the objectives of this study was to develop a protocol to use dynamic FDG 
PET scanning as a marker of inflammation with a view to trial novel anti- 
inflammatory drugs subsequently in the COPD patients. The requirements for 
conducting a drug study using the type of biomarker developed here is to estimate 
the number of subjects that would be required to detect a specific change. 
 
For the reproducibility phase, using 80% Power, one-sided alpha of 0.1 and a 
correlation = 0.52 and a percentage allowed change of 15% in the slope I needed 
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around 20 patients. Hence, I decided to go for this number in the reproducibility 
phase. To compare this data with the normal subjects without exposing too many 
healthy controls to the radiation I decided on six healthy subjects to complete the 




























Six patients were scanned in the feasibility phase and 20 patients during the 
reproducibility phase. Table 3.1 shows the comparative demographics between the 
COPD patients (combined feasibility and reproducibility phase) and the healthy 
controls for their age, spirometry, symptom scoring (COPD Assessment Test (CAT) 
score, St Georges respiratory questionnaire, modified MRC (mMRC) score as well 
as systemic inflammatory biomarkers (serum, white cell count (WCC), C reactive 
protein (CRP) and fibrinogen and cytokines as described in the methodology 
chapter). Out of the 20 patients scanned during reproducibility, three visit 2 scans 
could not be assessed (two patients dropped out, one scan was done with wrong 
settings). 
Variables Mean SEM Mean SEM p value 
COPD 
(n=26) 
 Controls (n=6)   
Age (years) 66.3 1.5 58.3 5.1 0.12 
FEV1 (L) 1.3 0.1 3.1 0.3 <0.0001 
FEV1 pp (%) 48.4 3.3 95.1 4.1 <0.0001 
FVC (L) 3.2 0.1 4.2 0.1 0.14 
FVCpp (%) 90.7 3.1 99.0 8.7 0.28 
FEV1/FVC ratio 0.4 0.02 0.80 0.3 0.04 
CRP (mg/L) 4.9 0.01 2.5 0.02 0.28 
Fibrinogen (g/L) 3.1 0.1 2.2 0.2 <0.0001 
WCC (x109) 8.2 0.6 5.3 0.3 <0.0001 
SGRQ total score 58.0 4.13 0 0 <0.0001 
CAT score 21.5 1.48 0 0 0.04 
mMRC dyspnoea score 1.9. 0.23 0 0 0.04 
neutrophil count (x109) 5.1 0.51 2.8 0.2 0.28 
Serum MPO (ng/ml) 195.1 18.3 126.5 6.2 0.06 
Serum IL8 (pg/ml) 107.6 23.0 59.1 10.0 0.29 
Serum IL6 (pg/ml) 12.1 4.9 4.3 1.3 0.06 
 
 
Table 3.1: shows comparative demographic characteristics of the COPD 
cohort (n=26) and the controls (n=6) with the respective values. 
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3.2 Normality distribution 
 
 
A normality distribution was performed to determine if it was appropriate to use 
parametric or non-parametric statistical analysis techniques. The distribution of both 
the groups (combined) in terms of demographic characters and the PET parameters 
were found to follow a non-normal distribution: hence I have used non- parametric 
techniques for all further statistical analyses. 
 
 
3.3 Patlak analyses 
 
 
3.3.1 Feasibility study 
 
 
The feasibility phase was performed initially with six stable COPD patients to 
validate and standardise methods of FDG analyses, and was also used to compare 




3.3.2 Comparison of various input functions (arterial, venous and 
image derived techniques) 
 
One of the primary aims of the feasibility phase of the study was to validate and 
standardise the PET scan protocols and then to evaluate whether time activity curves 
as generated by all three input functions (arterial blood, venous blood and image 
derived techniques) were comparable. As described in the Methods chapter, 
analyses were performed with arterial input functions (AIFs) derived from either the 
blood samples (plasma and whole blood) or the image-derived techniques derived 
from volumes of interest (VOI) drawn in the blood vessels (eg lumen of the aortic 
arch or descending aorta) in the dynamic PET images of the six COPD patients. 
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Estimates of Patlak slope (influx constant Ki) and intercept (initial volume of 
distribution) were calculated using the PMOD software from the time-activity 
curves for the volumes of interest (VOIs) previously segmented and registered to 
PET. Figure 3.1 shows a typical example of full inspiratory CT PET images in 
various lung lobes with respective time activity curves (Figure 3.2 colour coded 




Figure 3.1: Frames from a dynamic PET scan showing the lobar demarcation. 
 
 
Figure 3.2: Time activity curves in various lobes of the lung from an image 
derived input functioning. [Note the yellow line denotes the mean time activity 
curve for the whole lung].
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The time activity curves generated from all three input functions were found to be 




Figure 3.3a: Time activity curves from venous and arterial blood (whole blood 




Figure 3.3b: Patlak image from venous plasma CT (upper row), slope (middle 
row) and intercept (lower row). 
 
 
There was in general a good correlation demonstrated between both blood and 
image derived techniques. 
75  
These correlations were performed using the image derived and blood-derived data 
from the first six COPD patients in the feasibility phase of the study. Figures 3.4 a-d 





Figure 3.4a: Relationship between Patlak intercept derived from venous blood 




Figure 3.4b: Relationship between Patlak intercept derived from arterial blood 
vs image derived AIFs. 
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Figure 3.4c and 3.4d show these respective comparative data in column statistics. 
Some of the detailed statistical analyses between COPD and controls for all further 
comparisons have been added as supplemental tables in the Appendix section. 
 
 
Fig 3.4c shows comparative data for slope between all three modalities of AIF 
with no significant statistical difference (Histograms denote Mean and the 
bars the SEM. p=0.10). 
 
 
Similar non-significant results were shown when an analysis was made using all 
three input functions to measure the intercept (p value 0.35). Figure 3.4d 
summarises these results. 
Fig 3.4d shows these comparative data for intercept between all three 
modalities of AIF with no significant statistical difference (Histograms denote 
Mean and the bars the SEM, p=0.35) 
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Since there were no significant differences between the results for slope and 
intercept for these three methods of deriving the input function, for all the 
subsequent data analyses I used the image derived input functions. 
 
 
3.3.3 Summary inferences from feasibility phase 
 
 
The feasibility study thus helped us to optimise the PET/CT protocol using the first 




3.4 Reproducibility study 
 
 
The next phase of the study was to determine if the results from data from all the 
parameters derived using the Patlak analysis was reproducible across time between 
the two visits in the COPD patients, which was assessed using Bland-Altman plots. 
 
Tables 3.5 and 3.6 show the mean and the SEM of the Patlak data available from 
visits 1 and 2. 
 
 
Variable Mean SEM N 







Table 3.5: Mean and SEM of COPD patients for the Patlak parameters slope 
and intercept from visit one. 
 
 










Table 3.6: Mean and SEM of COPD patients for the Patlak parameters slope 
and intercept from visit two. 
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3.4.1 Reproducibility of slope 
 
 
The data between visits one and two were found to be reproducible with all data 
points within two standard deviations in Bland-Altman plots (Figure 3.7a). 
 
 
Figure 3.7b shows the mean plus SEM data for slopes between visits 1 and 2 of the 
COPD patients and, although not a measure of reproducibility, the similar results are 





Figure 3.7a: Bland Altman Plot analyses for slope showing acceptable 




Figure 3.7b: Mean and SEM of slope between two visits of COPD (Histograms 
denote Mean and the bars the SEM. p=0.36). 
 
 
3.4.2 Reproducibility of intercept 
 
 
Similarly, the data for intercept between visits 1 and 2 were found to be reproducible 
with all data points within two standard deviations in Bland-Altman plots (Figures 
3.8 and 3.9). 
 
Figure 3.8: Patlak intercept data in COPD patients between two visits is 
reproducible using B-A plot analyses. 
 
Figure 3.9: shows the mean plus SEM data for intercept between visits 1 and 2 of 
the COPD patients and, although not a measure of reproducibility, these similar 




Figure 3.8: Bland Altman Plot analyses for intercept showing acceptable 




Figure 3.9: Mean and SEM of slope between two visits of COPD (Histograms 
denote Mean and the bars the SEM, p=0.09). 
 
 




3.5.1 Comparison of slope and intercept between the COPD and the 
controls 
 
When these parameters were compared between the COPD patients and the healthy 
control, the intercept particularly was found to be higher in the controls compared to 




Figure 3.10: shows the data from COPD patients (n=20) and healthy controls 
(n=6) for the slope. (Histograms denote mean and the bars the SEM, p=0.11). 
 
 
Figure 3.11 shows the data from COPD Patients (n=20) and healthy controls 
(n=6) for the intercept and was significant with higher values observed in the 
controls. 
Fig 3.11: Comparison of Patlak intercept in COPD patients and the controls. 
(Histograms denote mean and the bars the SEM, p=0.005). 
 
 
Density effect: To explore the reason for the higher values of the intercept in healthy 
controls, I postulated that this may be an effect of lung density since healthy 
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controls have more lung tissue than COPD patients, who would have variable 
degrees of emphysema, resulting in higher lung density in the control subjects and 
hence greater volume of distribution (intercept), therefore resulting in a greater 
uptake when compared to the COPD patients. 
 
In this context I found a very strong correlation between the CT lung density 




Fig 3.12a: Shows good correlation between Patlak intercept and CT lung 
density (R2 value 0.78, p=0.01). 
 
 
Since there was a very good correlation between the intercept and lung density, it 
would seem appropriate to correct for lung density with a view to potentially 
improve the inflammatory signal. One way of doing this would be to divide the 
slope by the intercept to generate a corrected Ki. 
 
I also investigated the relationship between slope/intercept with lung CT density and 
found no significant correlation (Figure 3.12b, R2 =0.19, p value 0.68) suggesting 
that this index perhaps corrects for the lung density effect (as measured on CT) at 




Figure 3.12b: shows poor correlation between CT lung density and 
slope/intercept (R2 0.19, p=0.68). 
 
 
3.5.2 Comparison of slope/intercept between COPD and controls 
 
 
A comparison was also therefore made between the COPD and the controls for this 
corrected Ki value (slope/intercept). 
 
Figure 3.13 shows the results of slope divided by intercept, which showed no 




Figure 3.13: the results of slope divided by intercept for COPD and controls. 
(Histograms denote mean and the bars the SEM, p=0.7). 
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The values were reproducible with all data points within two standard deviations in 
Bland-Altman plot analysis (Figure 3.14). 
 
Figure 3.15 shows the mean plus SEM data for slopes divided by intercept between 
visits 1 and 2 of the COPD patients and, although not a measure of reproducibility, 






Figure 3.14: Bland Altman Plot analyses for slope/intercept showing 





Figure 3.15: Mean and SEM of slope between two visits of COPD (Histograms 
denote Mean and the bars the SEM, p=0.98) 
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3.5.3 Comparison between subgroups of COPD and controls 
 
 
A sub-analysis was also performed of the slope divided intercept data comparing by 
groups between the ex-smoker and smoking COPDs and the controls. There was a 
higher numerical value of slope/intercept in the current smoker COPD subgroup 
when compared to the others, but this failed to reach statistical significance (p value 





Figure 3.16: shows comparison of slope/intercept between COPD ex-smokers, 




3.5.4 Removal of areas of emphysema 
 
 
Since areas of emphysema in the lungs of COPD patients would contain little lung 
tissue, and hence may dilute any inflammatory signal, I also explored the possibility 
that removal of emphysematous voxels (areas with Hounsfield Units ≤ -950 on a full 
inspiration CT scan) would improve the signal obtained. This however did not show 




Figure 3.17: shows the slope divided by intercept corrected for emphysema 
(areas with Hounsfield Units ≤ -950 on a full inspiration CT scan) between the 




These data were also reproducible with all data points within two standard 
deviations in B-A analyses as shown in Figure 3.18a. Figure 3.18b shows the mean 
plus SEM data for this slope divided by intercept corrected for emphysema between 
visits 1 and 2 of the COPD patients and, although not a measure of reproducibility, 
these similar results (p value 0.98) are reassuring to observe. 
 
 
Figure 3.18a: Bland-Altman plot of the slope divided by intercept corrected for 




Figure 3.18b: shows no statistical difference of mean and SEM between the 
two visits for this data (histograms denote mean and bars the SEM, p=0.98). 
 
 
Comparison of slope/intercept corrected for emphysema between subgroups of 
COPD and controls: The slope/intercept data corrected for emphysema between the 
subgroups (COPD ex and current smokers and controls) was also assessed and, 
although higher numerically in COPD current smokers, this difference was not 




Fig 3.18c: comparison of slope/intercept corrected for emphysema between 
COPD ex- smokers, smokers and the healthy controls (Histograms denote 
Mean and the bars the SEM, p=0.23). 
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3.6 Lobar data analyses 
 
 
The lobar variation in Patlak corrected Ki (slope/intercept) was also investigated as 
a part of this study. Tables 3.4, 3.5 and 3.6 respectively show the mean and SEM 
values of slope divided intercept (Ki) for the various lobes between COPD (visits 1 
and 2) and controls. (Note: RUL = right upper lobe, LUL = left upper lobe, RLL = 
right lower lobe, LLL = left lower lobe). 
 
Table 3.4: COPD Visit=1 (Ki values) 
 
Variable Mean SEM 











Table 3.5: COPD Visit=2 (Ki values) 
 
Variable Mean SEM 












Table 3.6: Controls (Ki values) 
 
Variable Mean SEM 











The lobar data failed to reach any statistical significance between the two groups, 
although there was a trend for the upper lobe uptake to be greater in COPD 
compared with controls. 
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Figures 3.19 a-d show the comparative lobar data between the COPD and the 
controls with the corresponding p values. 
 
 
Figure 3.19a: Left upper lobe comparison between COPD and controls. 





Figure 3.19b: Right upper lobe comparison between COPD and controls. 




Figure 3.19c: Left lower lobe comparison between COPD and controls. 





Figure 3.19d: Right lower lobe comparison between COPD and controls. 
(Histograms denote Mean and the bars the SEM, p=0.69). 
 
To summarise, there was no statistically significant difference in the corrected Ki 
between the COPD and controls in the lobar data analyses. However, the upper lobe 
in COPD showed a trend to higher values (left upper lobe p value 0.1 and right 
upper lobe p value 0.09) compared to the lower lobe data when compared to the 
controls. 
91  
3.6.1 Lobar data analyses between subgroups of COPD and controls 
 
 
I also compared the lobar data between the two subgroups of studied COPD patients 
(smokers and ex-smokers) with the healthy controls. The current smokers had higher 
numerical readings for all the lobes, more so with the upper lobes, when compared 
to both the ex-smoker COPD and the controls, but again failed to reach clinical 
significance (right upper lobe p value 0.14, left upper lobe p value 0.34, right lower 
lobe p value 0.5, left lower lobe p value 0.6). 
 





Fig 3.20a: Comparison of lobar data (right upper lobe) between COPD 





Fig 3.20b: Comparison of lobar data (left upper lobe) between COPD smokers, 





Fig 3.20c: Comparison of lobar data (right lower lobe) between COPD 





Fig 3.20d: Comparison of lobar data (left lower lobe) between COPD smokers, 





3.7 Key summary points from the reproducibility and 
comparative analyses 
 
 Patlak analysis of FDG PET scanning of the lung gives a reproducible signal 
of lung inflammation in COPD patients. 
 There is a strong relationship between lung density and Patlak intercept, and 
dividing slope by intercept potentially could be a way to improve the inflammatory 
signal. 
 My study however showed no significant difference in these parameters 
between the COPD and the healthy controls. 
 The lobar data showed no significant difference either between the COPD and 
the controls. The upper lobe data uptake was, however, found to be higher but not 
statistically different in the COPD patients compared to the controls. 
 Other modes of analysis to correct for the density effect were therefore 
warranted. 
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3.8 Kinetic modelling analyses 
 
 
3.8.1 Parameters tested with the kinetic modelling 
 
 
Having established a strong relationship between the FDG uptake in the lungs and 
lung density with the Patlak analyses, a kinetic modelling analysis (as discussed in 
the methodology section) was then performed as an alternative way of investigating 
the data to account for the air fraction (Va) and blood fraction (Vb) components in 
the estimation of metabolic rate constant Ki. 
 
Table 3.8 summarises the mean and the SEM for the various parameters as 
measured by the kinetic modelling methods, described in the methods chapter. They 
are as follows: 
 
kiAoVb and kiPulmVb: Ki data estimated from aorta (KiAoVb) and pulmonary 
artery (kiPulmVb) image-derived AIFs using method 1 (Method 1 applies correction 
factor (1-Vb)/(1-Va-Vb)) 
 
kiAoVbVa and kiPulmVbVa: Ki data estimated from aorta (kiAoVbVa) and 
pulmonary artery (KiPulmVbVa) image-derived AIFs using method 2 to include air 
fraction (Va) from CT directly in the kinetic model estimation of blood fraction (Vb) 
and Ki. 
 
Table 3.7a shows the mean and the SEM for the various parameters as described in 
the kinetic modelling in COPD (visit 1). 
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Table 3.7a: visit 1 COPD (Mean and SEM of kinetic model parameters). 
 
 
Table 3.7b shows the mean and the SEM for the various parameters as described in 
the kinetic modelling in COPD (visit 2). 
 
 













Table 3.7b: visit 2 COPD (Mean and SEM of kinetic model parameters). 
 
 
Table 3.8 shows the mean and the SEM for the various parameters as described in 
the kinetic modelling in the healthy controls. 
 
 













Table 3.8: Controls (Mean and SEM of kinetic model parameters). 
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3.8.2 Comparison of all kinetic model data between the two visits of 
COPD and reproducibility 
 
All data were reproducible between the two visits for the COPD patients. 
 
 
KIAoVb: The values were reproducible with all data points within two standard 
deviations in a Bland-Altman plot analysis (Figure 3.21a). Figure 3.21b shows the 
mean plus SEM data for KiAoVb between visits 1 and 2 of the COPD patients and, 











Figure 3.21b: shows no statistical difference of mean and SEM between the 
two visits for this data (histograms denote mean and bars the SEM, p=0.93). 
 
 
KiPulmVb: The values were reproducible with all data points within two standard 
deviations in a Bland-Altman plot analysis (Figure 3.21c). Figure 3.21d shows the 
mean plus SEM data for KiPulmVb ((Ki corrected for Vb and Va retrospectively 
based on pulmonary artery image-derived AIF) between visits 1 and 2 of the COPD 
patients and, although not a measure of reproducibility, the similar results are 




Figure 3.21c: Bland-Altman plot of KiPulmVb in COPD patients between visits 





Figure 3.21d: shows no statistical difference of mean and SEM between the 
two visits for this data (histograms denote mean and bars the SEM, p=0.74). 
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KiAoVbVa: The values were reproducible for KiAoVbVa with almost all data points 
within two standard deviations in a Bland-Altman plot analysis (Figure 3.21e). 
 
Figure 3.21f shows the mean plus SEM data for KiAoVbVa (based on aortic image 
derived AIF) between visits 1 and 2 of the COPD patients and, although not a 




Figure 3.21e: Bland-Altman plot of KiAoVbVa in COPD patients between visits 





Figure 3.21f: shows no statistical difference of mean and SEM between the 
two visits for this data (histograms denote mean and bars the SEM, p value 
0.76). 
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KipulmVbVa: The values were reproducible for KiPulmVbVa with all data points 
within two standard deviations in Bland-Altman plot analysis (Figure 3.21g). 
Figure 3.21h shows the mean plus SEM data for KiPulmVbVa (based on pulmonary 
artery image derived AIF) between visits 1 and 2 of the COPD patients and, 





Figure 3.21g: Bland-Altman plot of KiPulmVbVa in COPD patients between 





Figure 3.21h: shows no statistical difference of mean and SEM between the 
two visits for this data (histograms denote mean and bars the SEM, p=0.86). 
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3.8.3 Comparison of kinetic modelling data between the COPD and 
healthy controls 
 
There was no statistical significance between the COPD as a whole group and the 
controls for KiAoVb and KiAoVbVa parameters. However, the parameters 
KipulmVb showed statistically significantly higher values in the COPD patients 
compared to controls (p value of 0.04), and the difference between COPD and 
controls just failed to reach statistical significance for KiPulmVbVa (p value 0.08). 
 
These results are summarised in Figures 3.22 a-d. 
 
Figure 3.22a: KiAoVb comparison between COPD and controls (Histograms 
denote Mean and the bars the SEM, p=0.86). 
 
 
Figure 3.22b: KiAoVbVa comparison between COPD and controls (Histograms 





Figure 3.22c: KiPulmVb: comparison between COPD and Controls. 
(Histograms denote Mean and the bars the SEM, p=0.04). 
 
 
Figure 3.22d: KiPulmVbVa: comparison between COPD and the controls. 
(Histograms denote Mean and the bars the SEM, p=0.08). 
 
 
3.8.4 Comparison between subgroups of COPD and controls 
 
 
Similar results were also obtained for KiPumVb and KiPulmVbVa when the COPD 
group was subdivided according to their smoking status, with higher inflammation 
observed in the smoking COPD patients. KiAoVb and KiAoVbVa showed a trend 
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to higher values in the smoking COPD patients, which just failed to reach statistical 
significance. (Table 3.9 and Figures 3.23 a-c summarise these observations). A post 
hoc analyses using KiPulmVb also showed significant differences between the 












(mean ± SEM) 
 
p value 
kiAovb 0.008 ±0.0002 0.013±0.0003 0.008±0.0001 0.06 
KiAoVbVa 0.007±0.0009 0.013±0.0003 0.007±0.0006 0.07 
KiPulmVb 0.008±0.0001 0.010±0.0001 0.006±0.0004 0.04 
KiPulmVbVa 0.007±0.0006 0.010±0.0001 0.006±0.0004 0.06 
 
Table 3.9 shows the summary of the results between COPD smokers, ex-
smokers and the controls. 
 
 
Figures 3.23 a, b, c and d show the results for the parameters in the compartmental 
analysis in COPD ex-smokers, COPD smokers and the healthy controls. 
 
Figure 3.23a: KiAoVbVa between the three groups (histograms denote the 








Figure 3.23b: KiAoVb between the three groups (histograms denote the mean 







Figure 3.23c: KiPulmVb between the three groups (histograms denote the 
mean and the bars the SEM, p=0.04, comparsion between COPD smokers and 





Figure 3.23d: KiPulmVbVa between the three groups (histograms denote the 
mean and the bars the SEM, p=0.06). 
 
 




From the above results, given that KiPulmVb was the parameter that demonstrated 
most significant difference between COPD (smokers and ex-smokers) compared 
with controls, I chose this parameter to explore possible correlations with clinical 
parameters (FEV1, FEV1pp, FVC, FVCpp, FEV1/FVC ratio, St George's 
questionnaire score, CAT score, MRC score), and markers of inflammation 
(neutrophil count, MPO, IL8, A2MG, IL6, WBC, CRP and fibrinogen) in COPD 
patients. 
 
Using Pearsons Correlations Coefficient analysis no significant correlations were 
however shown between KiPulmVb and any of these combined groups of COPD 
and controls (Tables 3.10 and 3.11), or in COPD patients alone (Tables 3.12 a and 
b). 
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 FEV1 FEV1pp FVC FVCpp FEV1/FVC SGRQ CAT mMRC 
R value -0.20 -0.27 0.23 0.15 -0.12 0.11 0.19 0.09 
p value 0.29 0.15 0.22 0.43 0.53 0.56 0.32 0.64 
N = 26 26 26 26 26 26 26 26 
 
Table 3.10: Correlations of KiPulmVb with clinical variables in the combined 
COPD and control group 
 
 
 IL8 A2MG IL6 WBC CRP Fib MPO 
R value -0.11 0.16 -0.13 0.29 -0.15 -0.12 -0.13 
p value 0.57 0.41 0.52 0.13 0.43 0.52 0.52 
N = 26 26 26 26 26 26 26 
 
Table 3.11: Correlation of KiPulmVb with markers of inflammation (all serum 
samples) in combined COPD and control groups. 
 
 
Tables 3.12a and b show no significant correlations of KipulmVb with the various 
clinical parameters and inflammatory markers respectively in the COPD patients. 
 
 
 FEV1 FEV1pp FVC FVCpp FEV1/FVC SGRQ CAT mMRC 
R value 0.07 -0.05 0.35 0.26 -0.18 -0.22 -0.06 -0.18 
p value 0.72 0.79 0.09 0.21 0.39 0.30 0.75 0.39 
N = 20 20 20 20 20 20 20 20 
 




Pearson correlation coefficients of KiPulmVb with the various blood 
inflammatory markers in COPD patients  
 MPO IL8 A2MG IL6 WBC CRP Fibrinogen 
R value -0.17 -0.14 0.13 -0.14 0.26 -0.19 -0.21 
p value 0.42 0.51 0.53 0.49 0.22 0.38 0.32 
N = 20 20 20 20 20 20 20 
 
Table 3.12b: Correlation of KiPulmVb with markers of inflammation (all serum 
samples) in the COPD group. 
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In seven COPD patients who managed to provide us with an induced sputum 
sample, I measured markers of inflammation (sputum MPO, IL8, A2MG, IL6 and 
neutrophil count) and found no significant correlation with KiPulmVb (Table 3.13). 
 
 
Pearson correlation coefficients of KiPulmVb with the various cytokines from 
the 
induced sputum in COPD 
 MPO IL8 A2MG IL6 WBC 
R value -0.02 0.33 0.27 0.66 0.09 
p value 0.96 0.46 0.54 0.10 0.83 
N = 7 7 7 7 7 
 
 
Table 3.13: Correlation of KiPulmVb with markers of inflammation in the 
sputum of COPD patients. 
 
 




 The data between both the visits for the COPD patients were reproducible. 
 
 Kinetic modelling analysis accounts for both air and blood volume fraction 
components. 
 Markers such as KiPulmVb and KiPulmVbVa hold promise to be better 
indicators of lung inflammation in dynamic FDG PET scanning. 
















3.10 SUV analyses 
 
 
3.10.1 SUV measurement 
 
SUV is a semi-quantitative ratio of tissue radioactivity ([18F FDG uptake) within the 
region of interest to the injected tracer activity, adjusted for body weight and the 






SUVmax measured, as an index of SUV measurement, was reproducible with all 
data points within two standard deviations in a Bland-Altman plot analysis (Figure 
3.24a). Figure 3.24b shows the mean plus SEM data for SUVmax between visits 1 
and 2 of the COPD patients and, although not a measure of reproducibility, the 
similar results are reassuring to observe. 
 
 
Fig 3.24a: Bland Altman plot comparing SUV max between the two visits. 
 
 
Figure 3.24b shows the histograms of mean +SEM for the SUVmax between the 2 




Figure 3.24b: SUVmax in visit 1 and 2 in COPD patients (Histograms denote 
Mean and the bars the SEM, p value 0.25). 
 
 
3.10.3 Correlation with lung density 
 
 
A good correlation was noted between the SUV max and lung density from full 
inspiratory CT scan (Figure 3.25) similar to results from the Patlak analyses (R2 
0.76, p=0.05). 
 




The SUVmax corrected for density was therefore also calculated. Table 3.14a and 
3.14b show the mean and the SEM results for SUV max, as well as SUVmax 


























Table 3.14a and 3.14b 
 
 
3.10.4 Comparison between COPD and the controls 
 
 
Table 3.15a and 3.15b show the mean and the SEM for the SUVmax and SUVmax 




























There was however no significant difference between the COPD and the controls 





Figure 3.26: shows no statistically significant difference in SUVmax between 
the COPD and the healthy controls (Histograms denote the mean and the bars 
the SEM, p=0.16). 
 
The SUV max corrected for density showed higher numerical values in COPD than 
controls, although this difference just failed to reach statistical significances (p value 





Figure 3.27: SUVmax corrected for density shows higher value in COPD 
compared to controls (histograms denote the mean and the bars the SEM, 
p=0.05). 
 
3.10.5 SUV using kinetic modelling correction 
 
 
I also assessed the SUV after correcting for air and blood fraction based on the aorta 
using the kinetic model analyses (applying a 1-Va-Vb correction), and found the 
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corrected SUV max was significantly higher in the COPD patients compared to the 




Figure 3.28: SUV corrected for density using kinetic modelling analyses in 
COPD and controls (Histograms denote Mean and the bars the SEM, p=0.04). 
 
 
3.11 Key summary points of SUV analyses 
 
 
 Lung SUVmax was reproducible between visits 1 and 2 in the COPD patients. 
 
 When corrected for lung density SUVmax shows differences between COPD 
and controls and could be a potential marker of lung inflammation in COPD 
patients. 
 
3.12 Assessment of vascular inflammation 
 
 
3.12.1 Assessment of vascular inflammation 
 
 
Vascular inflammation in the aorta was also assessed in the COPD patients and the 
healthy controls using combined 18F-FDG PET/CT scan technique as a sub study. 
Since these analyses needed only static PET scan data, I also included data from 10 
ex-smokers with normal spirometry who had undertaken a previous PET scan. 
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Aortic 18F-FDG uptake was measured as maximum standardised uptake value 
(SUV). Emphysema as before was expressed as % of low attenuation areas with HU 
of less than −950 within both lungs. 
 
Table 3.16 shows the characteristics for these groups. 
 
 






Age (years) 66.4 ± 7.5 59.7 ± 12.8 61.6 ± 5.5 
Sex (M: F) 18: 6 4: 4 6: 4 
Smoking history (pack years) 39.0 ± 7.1 0 32.8 ± 19.6 
FEV1 (% predicted) 48.4 ± 16.5 104.5 ± 17.5 97.3 ± 17.6 
Emphysema ((% < -950HU) 13.9 ± 13.0 0.66 ± 0.6 2.4 ± 4.7 
 
Table 3.16 shows the important characteristics in the three groups. 
 
 
3.12.2 Reproducibility between the two visits for COPD patients 
 
 
Figure 3.29a shows reproducibility of aortic arch SUVmax between visits 1 and 2 
for the COPD patients with most data points within two standard deviations in a 
Bland-Altman plot analysis. 
 
 
Figure 3.29a: shows good reproducibility of mean SUVmax (Aortic arch) 
between the two visits. 
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Figure 3.29b shows reproducibility between visits 1 and 2 for the COPD patients in 
respect of SUV max from ascending aorta with most data points within two standard 
deviations in a Bland-Altman plot analysis. 
 
 
Difference vs. average: Bland Altman of mean S U V (Max) AA 
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Figure 3.29b: shows good reproducibility of mean SUVmax AA (Ascending 
aorta) between the two visits. 
 
Figure 3.29c shows reproducibility between visits 1 and 2 for the COPD patients in 
respect of SUV max from descending arch with most data points within two 
standard deviations in a Bland-Altman plot analysis. 
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Figure 3.29c: shows good reproducibility of Mean SUV (max) of DA (SUV of 
Descending Aorta). 
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Figure 3.29d shows acceptable reproducibility of the TBR data as well between the 
two visits of the COPD patients with most data points within two standard 
deviations in a Bland-Altman plot analysis. 
 
Difference vs. average: Bland Altman of mean TBR Aorta 
 
 





3.12.3 Comparison between COPD and the controls 
 
 
Aortic maximum SUV (SUVmax) [mean±SEM] was significantly higher in COPD 
patients (3.77 ± 0.30), compared with healthy volunteers (3.25 ± 0.45) and ex- 
smokers (2.81 ± 0.34) with a p value of <0.05 (Figure 3.30a). 
 
 
Figure 3.30a: Aortic maximum SUV (SUVmax) was significantly higher in 




However, when assessed with the Mean and Max Target to Background ratio (TBR)  
as the other index of measuring vascular inflammation, there were no significant 
differences between the COPD and the healthy controls groups for all. Mean TBR 
COPD (1.17 ± 0.20), Mean TBR Healthy Volunteers (1.133 ± 0.12) and Mean TBR 





Figure 3.30b: Mean TBR values between COPD and the controls (p=0.85). 
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3.12.4 Correlations of SUV max aortic arch (SUVmax and TBR with 
clinical parameters (in COPD patients) 
 
Positive correlations were observed in the COPD patients with these following 
markers. 
 
 St George's Questionnaire: SUVmax (r = 0.53, p=0.006), TBR (TBR from 
ascending arch) (r = -0.54, p=0.0058) 
 CAT score: SUVmax (r = 0.56, p=0.0043), TBR (r = 0.44, p=0.02) 
 FEV1/FVC Ratio: SUVmax (r = 0.46, p=0.02), TBR (r = -0.41, p=0.04) 
 
No significant correlations were demonstrated between these indices and other 
parameters in COPD patients. They are as follows: 
• FEV1: SUVmax (r=0.12, p=0.56) TBR (r= 0.18, p=0.68) 
• CRP: SUVmax (r=0.10, p=0.6) TBR (r= 0.11, p=0.7) 
• WCC: SUVmax (r=0.19, p=0.46) TBR (r= 0.20, p=0.57) 
• Fibrinogen: SUVmax (r=0.25, p=0.13) TBR (r= 0.28, p=0.18) 
 
3.12.5 Correlations in all groups 
 
Further analyses in the combined results of all three groups showed positive 
correlations with the following variables: 
 FEV1: SUVmax (r = -0.50, p=0.0007) 
 FVC: SUVmax (r = -0.37, p=0.0015) 
 FEV1/FVC Ratio: SUVmax (r = -0.428, p=0.004) 
 Smoking: Emphysema score (r = 0.56, p=0.0002) 
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 Fibrinogen: TBR (r = 0.44, p=0.017) 
 Emphysema score (less than -950 HU): FEV1 (r = -0.52, p=0.0005), Predicted 
FEV1 (r = -0.59, p<0.0001), FEV1/FVC ratio (r = -0.68, p<0.0001) 
 
3.13 Key summary points of vascular analyses 
 
In summary, the SUVmax measurements were reproducible. Aortic maximum SUV 
(mean±SEM) was significantly higher in COPD patients compared with the healthy 
volunteers. However, similar results were not elicited when TBR was used as the 
index of inflammation. 18F-FDG PET/CT could therefore potentially be a 






















4.1 Significance of dynamic PET/CT scanning 
 
 
There is a growing body of literature supporting the use of FDG PET imaging to 
assess the neutrophilic burden in the lungs in a number of pulmonary diseases. 
 
We also know that chronic lung inflammation is a characteristic feature of COPD 
and involves cells such as neutrophils, macrophages, T lymphocytes and augmented 
concentrations of inflammatory cytokines, and the resultant neutrophil alveolar 
infiltration would be expected to be associated with an increased cellular 
metabolism and glucose consumption, and consequently increase in FDG activity in 
COPD lungs. Existing evidence also suggests that neutrophils contribute primarily 
to the increased uptake of 18F FDG in lung inflammation and that the FDG-PET 
signal potentially correlates with the presence of activated neutrophils [154, 176]. 
 
Further understanding of the mechanisms that lead to increased 18F FDG uptake 
using dynamic PET scans in inflammatory conditions would be therefore helpful in 
interpreting what its uptake means in the context of lung inflammation and 
consequent potential targeted anti-inflammatory treatment in chronic lung 
conditions like COPD. This, along with further standardisation of all the 
methodologies including assessing reproducibility, is crucial to enhance our 
understanding of this imaging technique, both in clinical practice and for 
translational research. 
 
The advantages of PET imaging include its non-invasiveness, the opportunity of 
quantification, and the ability to assess the entire lung as it enables quantification of 
radioactivity throughout the lungs, in airspaces and interstitium, enabling study of 
the behaviour of key inflammatory cells in their native micro-environment [176]. 
Investigation of 18F FDG uptake in the lungs in diffuse lung diseases such as COPD 
120  
may therefore be an important tool in assessing lung inflammation, monitoring 
disease progression, as well as assessing treatment efficacy. 
 
Some clinical studies have previously used PET to acquire static lung images. In 
such studies the subject is injected with the radioactive ligand and scanned after it 
has reached equilibrium in the body, usually after 45-50 minutes. In contrast, 
dynamic scan starts image acquisition immediately and follows the course of the 
tracer dynamically. This permits the radiotracer concentration within the body to be 
observed in real time, and therefore is considered potentially more informative and 
quantitative [176]. 
 
It is well known that pattern and distribution of structural parenchymal 
abnormalities can be assessed by high resolution CT scanning (HRCT). However, 
HRCT is a purely structural imaging technique on which only indirect inferences 
regarding inflammation can be made. PET, on the other hand, potentially offers the 
ability to noninvasively investigate cellular metabolism in vivo. Combining PET/CT 
imaging thus has the potential to provide both structural and inflammatory 
information and provides advances in the field. [176]. 
 
 
4.1.1 Evidence so far supporting the use of dynamic PET scanning in 
lung diseases as a biomarker of lung inflammation 
 
The United States Food and Drug Administration define a biomarker as "a defined 
characteristic that is measured as an indicator of normal biological processes, 
pathogenic processes, or responses to an exposure or intervention, including 
therapeutic interventions" [142, 177]. It is also known that the utility of any imaging 
biomarker will rely on a number of factors, including its reliability and accuracy in 
quantifying the process it is intended to measure, its reproducibility within subjects, 
and its dependence on observer interpretation [142]. 
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Studies have previously shown that positron emission imaging following injection 
of 18F-fluorodeoxyglucose could be used to monitor neutrophil metabolic activity in 
vivo [154] and have also shown marked increase in FDG uptake in the lungs in 
animal models of pneumonia [178]. An in vitro study has previously also shown that 
the uptake of deoxyglucose by neutrophils reflects both priming and activation of 
the cell [179]. The sustained neutrophil presence and activation in lung 
inflammation [154] is likely to be orchestrated by alveolar and interstitial 
macrophages. Accumulation of macrophages can also be measured noninvasively by 
PET imaging of 11C-labelled PK11195 (a ligand that binds specifically in 
macrophages) and increased lung uptake, as has previously been demonstrated in 
rabbit lungs in response to particulate challenge [180]. There is also evidence that 
chronic activation of neutrophils is associated with the development of pulmonary 
fibrosis [181]. Studies have also shown that there was an increase in the radiotracer 
concentration of FDG in regions of increased lung fibrosis in idiopathic pulmonary 
fibrosis (IPF) [182]. 
 
FDG PET studies have shown interesting results in ARDS and acute lung injury. 
Bellani and colleagues [183] studied the utilisation of FDG PET in patients with 
ARDS and found that the relationship of FDG uptake and lung density followed two 
patterns; most of the patients had highest FDG uptake in regions with the highest 
density and, in some patients, the uptake was higher in normally or poorly aerated 
regions than in non-aerated regions. This study again reinforced the potential of 
FDG as a possible surrogate of lung inflammation, as the normally aerated lungs in 
ARDS are known to have higher influx of inflammatory cells [183]. 
 
These studies have thus been considered to be useful for further development of 
techniques for non-invasive imaging of the various components of the inflammatory 
process in the lungs, and for assessing the therapeutic modification of lung 
inflammation [181]. 
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Current evidence in COPD: Very few studies have previously investigated the 
effectiveness of dynamic PET imaging in COPD patients [152, 154, 184]. One such 
study has shown increased pulmonary uptake of 18FDG in patients with COPD and 
that this FDG uptake related to the presence of emphysema [152]. This study 
however only studied the Patlak analysis as a method of assessing FDG uptake in 
the lungs. Also, the reproducibility of the Patlak analyses was not assessed in this 
study. In another study, however, good reproducibility was shown in the assessment 
of FDG PET as a surrogate of inflammation in COPD patients [184]. 
 
However this was performed on a small number of COPD patients, again using just 
the Patlak analyses. Jones and her colleagues also showed similar results in six 
stable COPD patients [154] and found correlations between the lung PET signal and 
markers of inflammation in sputum in a small study of six COPD patients. Hence 
further exploration to optimise all of the methods to assess FDG uptake in the lungs, 
as a surrogate measure of lung inflammation in COPD patients, in a larger cohort of 
COPD patients was merited. 
 
 
4.1.2 Significance of my study 
 
 
A primary goal in this study was therefore to standardize the protocol for FDG PET 
imaging of lung inflammation, its reproducibility and, in particular, to investigate 
the various methods of analysis of FDG PET imaging in COPD as the target 
condition for potential anti-inflammatory therapies. 
 
My study thus aimed to compare the various methods of assessing FDG lung uptake 
in dynamic (Patlak analyses, 2 compartmental kinetic modelling) and static (SUV 
measurement) FDG PET lung imaging in COPD patients and in healthy controls. As 
is known, blood and air comprises a significant proportion of the lung and could 
result in a significant underestimation of the FDG uptake in the lung parenchyma. 
Without correcting for these effects, the sensitivity of the PET signal from the lungs 
would be reduced. This was the justification for the application of the various 
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methods in this study to investigate and correct for these effects. 
 
In the following sections each aspect of my study will be discussed in more details. 
 
 
4.2 Feasibility study 
 
 
The main aim of the feasibility phase was to develop a local protocol and method of 
analysis FDG PET/CT as a surrogate marker of lung inflammation in COPD 
patients. This was successfully achieved in this phase by applying various arterial 
input functions (AIF). This phase of the study demonstrated comparability of the use 
of blood-derived (venous and arterial) and image-derived techniques in COPD 
patients and is the first study to demonstrate this in COPD patients. As a result, it is 
now possible to assess dynamic FDG pet imaging less invasively without the need 
for arterial blood sampling. 
 
 
4.2.1 Challenges of image-derived analysis of dynamic FDG PET 
technique 
 
A prerequisite for the analysis of the lungs is the acquisition of an input function in 
the form of a blood time–activity curve. The input function typically involves 
sequential blood sampling, a process that is invasive, prone to measurement 
artefacts, exposes the clinical staff to radiation and blood, and adds costly laboratory 
procedures. To avoid or minimize manual blood sampling, substantial effort has 
been devoted to developing alternative techniques such as image derived input 
functions. 
 
AIFs could thus also be derived from dynamic images without the need for blood 
sampling. This is achieved from a volume of interest (VOI) drawn over a large 
thoracic vessel such as pulmonary artery or the aorta. The application of accurate 
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VOI is dependent on image segmentation, and could be affected by motion artefacts 
[185], which were corrected for in my study. One disadvantage of this method is 
that the time-activity curve is for whole blood and not plasma, and that the activity 
determined may be affected by partial volume effect (PVE) [164]. This is due to the 
limited spatial resolution of PET, which results in a confounding factor in the 
reconstructed image from any object smaller than the spatial resolution of the 
system. The PVE is of two types; spillover effects (or cross-contamination) and the 
tissue fraction effect (TFE) [155, 186, 187]. The simplest method to lessen spillover 
effects is to enhance the spatial resolution [156], which was applied in my study. 
The way to deal with TFE is discussed in a later section. 
 
 
A correction for image-derived arterial input functions (AIF) based on comparing 
two late blood calibration samples with the AIF from a blood pool region of interest 
(ROI) using a 2-parameter model describing the activity of blood and that from the 
spillover into the time-activity curve for the blood pool ROI, has also been described 
[156]. My results are based on image-derived AIFs without correction by whole 
blood samples, as also reported by Holman [155], and without the plasma to whole 
blood ratio correction (~1.07) reported by Coello and colleagues [188]. Correction 
of image-derived AIFs by whole blood samples based on an average of the last 30 
minutes were also investigated in my study, but results have not been reported 




4.2.2 Other challenges of combined PET/CT imaging methodology 
 
 
The annihilation photons in PET are subject to attenuation as they travel through the 
imaged object. This effect reduces the number of photons detected in each line of 
response [189]. CT-based attenuation correction is an important step in correcting 
for this in quantitative FDG PET imaging. This results in shorter acquisition times, 
improves image quality and quantitative accuracy. However, due to the temporal 
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difference between PET and a single attenuation map from CT, typically available in 
routine clinical scanning, motion artefacts and errors observed in matching the 
attenuation-corrected scan to the PET images could add to the errors. Reducing the 
spatial mismatch of the PET and CT reconstructed images remains a challenge and 
has been extensively explored in the literature [187]. This, together with PVE, can 
lead to further errors in analysis [189, 190]. A model of a joint correction approach, 
incorporating a model of motion blurring, PVE, and object size/shape could be a 
way forward [190]. 
 
CT scanning also introduces challenges with respect to the effect of respiratory 
motion on the co-registration of the PET-CT images, which has important 
implications for the reliability of region of interest placement for small lung regions. 
Artefacts can result from patient and organ motion and differences between the 
breathing protocols used in PET and CT. These artefacts affect the accuracy of the 
registration and attenuation correction, seriously compromising the accuracy of 
activity quantification [191, 192]. Asking the patient to hold the breath during the 
CT scan, as is usually performed in diagnostic CT studies, can lead to artefacts 
because of the certain mismatch between a specific stage of the breath cycle during 
the CT and the average of many breathing cycles in the PET images. Nonetheless, 
even if the patient is allowed to breathe normally during the whole PET/CT study, 
because of the fast CT scan time, the diaphragm is visualised in a single position 
that is different from the mean position of PET images or in the course of respiratory 
motion. Therefore, mismatch of attenuation correction CT and PET can cause 
artefacts particularly near the diaphragm [193, 194]. A respiratory-gated analysis to 





Using the Bland Altman analyses my study demonstrated a good reproducibility 
between visits 1 and 2 of the COPD patients with regard to all of the parameters of 
PET imaging that I investigated. This is again the first study to investigate the 
reproducibility of dynamic PET scanning in stable COPD patients, using Patlak 
analysis and kinetic modelling methods as well as SUV measurements. All of the 
results showed good repeatability between the two visits for all of the parameters. 
Thus, dynamic PET/CT using the protocol and analysis techniques used in this study 
can be utilised to assess the effects of interventions in future studies. 
 
Models used to assess FDG activity usually use an iterative fitting method to find 
the least squares between the measured and calculated values over time, which may 
lead to methodological challenges such as the over fitting of model parameters and 
result in poor reproducibility, especially when handling noisy data [195]. It was 
therefore reassuring to see a good repeatability of the data in my study. Chen and 
her colleagues also showed good reproducibility in a cohort of COPD patients; 
however this study only assessed the indices of the Patlak analysis [184]. 
 
However, all indices of repeatability in my study were performed by one observer. 
A study in 13 IPF patients investigated the reproducibility of pulmonary 18F-FDG 
PET/CT [182]. The study demonstrated excellent short-term reproducibility between 
the two scans (2 weeks apart) with very good intra-observer agreement. 
Some bias was observed between observers, and the authors concluded that serial 
studies would benefit from analysis by the same observer. This is the approach that I 
adopted in my study. 
 
It would nevertheless be important to perform a study, with inter observer’s 
repeatability comparing all the different indices of PET analyses (SUV vs Patlak 
analyses vs kinetic model analyses) in a COPD cohort. 
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4.4 Static vs. dynamic PET scanning 
 
 
4.4.1 Static imaging 
 
 
Static PET imaging of the lung measures the standardized uptake value (SUV). SUV 
is a simple and straightforward index of tracer uptake, but it introduces 
quantification bias since it is neither directly linked to any physiological process nor 
independent on blood flow and blood-to-tissue tracer transportation [185]. 
 
In contrast, dynamic PET studies offer the possibility of full kinetic modelling. 
Kinetic modelling offers a quantitative description of tracer behaviour by taking into 
account the blood flow and the transportation rate constants between the blood and 
the tissue, which is particularly important in lung studies. 
 
My study showed that the SUVmax when corrected for the lung density showed a 
trend to higher values in the COPD group compared to the controls. This difference 
was greater and reached a statistical significance (p=0.04) when the SUVmax was 
calculated using correction for Va and Vb. Similar results were shown by Torigian 
and colleagues who calculated lung parenchymal volume (L) (in cm³), excluding 
large and small pulmonary vessels, emphysema volume (E) (in cm³) based on a - 
910HU threshold, fraction of lung emphysema (F=E/L), and mean attenuation (HU) 
of non-emphysematous lung parenchyma from the CT images [196]. They also 
calculated a partial volume correction (PVC) of lung SUVmax to account for air, 
emphysema and lung tissue density, and this corrected SUVmax (corrected for the 
mixture of air and lung parenchyma at the microscopic level) showed a strong and 
positive correlation with extent of lung emphysema. The uncorrected SUVmax in 
this study however did not show significant correlations. This reinforces the fact that 
pulmonary inflammation may only be detectable when 18F-FDG uptake is corrected 
for the partial volume effect using data provided by chest CT images. 
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4.4.2 Dynamic PET imaging 
 
 
The hypothesis in my study was that dynamic PET scanning would be a more robust 
way of assessing lung inflammation in COPD patients. It nonetheless failed to show 
a significantly enhanced inflammatory signal in the COPD patients compared with 
control subjects using the conventional Patlak analyses. 
 
This is in contrast to other previous studies in COPD using Patlak analyses that 
demonstrated more positive outcomes in this condition [152, 154, 184]. 
 
FDG PET studies in other chronic lung diseases, such as cystic fibrosis, and in acute 
inflammatory lung diseases, such as pneumonia, have also shown significantly 
raised FDG uptake as measured by Ki compared to healthy controls [178, 197]. 
However, these conditions are characterised by increased bacterial colonisation, 
with marked increased numbers of neutrophils present in the lungs in these 
conditions. In stable COPD by contrast, neutrophilic inflammation in the lungs is 
less prominent and FDG PET may not be sensitive enough to pick up the subtle 
increase in neutrophilic inflammation in the lungs in COPD patients. 
 
In addition, it is important to remember that lack of FDG activity does not 
necessarily signify lack of lung inflammation in the COPD patients. For example, in 
patients with bronchiectasis an enhanced indium-111 labelled granulocyte activity 
indicated significant migration of neutrophils, which correlated the sputum volume 
and the extent of bronchiectasis on CT [143], but there was little FDG uptake on 
PET imaging [178]. In a further study, Jones and colleagues provided an explanation 
for this by demonstrating that 18FDG uptake is associated with some but not all 
neutrophil activities requiring energy, and is also related to the migrational and the 
polaroid state of the cell [179]. 
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The other explanation of a poor inflammatory signal using Patlak analyses, as 
observed in my study, may be the need to consider for correction for the potential 
contributing factors such as the TFE in the lung, which is a high vascular organ. 
 
 
4.4.3 Correction for the tissue fraction effect 
 
 
The TFE, as mentioned previously, is a component of the partial volume effect and 
is the result of the finite size of an image voxel. A single voxel within the lung will 
contain air and multiple tissue components including blood and lung parenchyma. 
The resulting voxel value, when being assessed for lung inflammation, will then be 
an average of the tracer concentrations within that voxel (including blood and air) 
and not just the signal from the lung parenchyma. 
 
The significance of correcting the air component of the TFE has been investigated in 
previous studies [198, 199]. In one such study Groves et al had shown increased 
FDG uptake in denser regions of lung fibrosis, where there is a greater tissue 
component compared to the more normal areas of lung parenchyma [200]. Thus, in 
regions of the lungs with enlarge air spaces, as is often the case in severe COPD 
patients with emphysematous lung, the TFE will have more of an influence on the 
signal. As shown in a previous study, if the TFE is taken into account the uptake 
distribution could be more uniform across the lung with reduced inter- and intra- 
subject variability [198]. 
 
In my study a clear relationship was shown between lung density (as measured by 
CT scanning) and the FDG uptake.  One way of correcting for the air component 
and thus enhancing the inflammatory signal when using the Patlak method could   
be to correct the effect of density. In my study I was able to show that the difference 
in the FDG PET signal from the lungs between control and COPD was greater when 
corrected for density, although this difference still failed to reach statistical 
significance. 
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An optimal assessment of lung inflammation using the dynamic FDG PET scanning 
may therefore need better correction for the TFE. The compartmental model 
analysis allows for this and includes a correction for the blood volume effect. Using 
this approach I showed increased FDG uptake in the lungs, suggesting increased 
inflammation in the lungs of COPD patients compared to the healthy controls as 
measured by an increase in the kinetic modelling indices (KipulmVb and 
KipulmVbVa). 
 
A similar approach has also been recently advocated by Coello et al who suggested 
a quantitative analysis, which corrects for the presence of air and blood in the lung, 
enabling direct estimation of the metabolic rate of FDG in lung tissue [188]. This is 
a more robust way of correcting for the blood and the air effect and is equivalent to 
method 2 of the compartmental analysis in my study. 
 
In diffuse diseases like COPD, estimation of 18F-FDG analysed previously using the 
Patlak graphical approach have used Patlak intercept as a surrogate to correct for air 
[178]. These previous studies [152, 154, 184] employing the Patlak method did not 
specifically include any correction for blood activity to the lung ROI. The concept 
of the use of Patlak intercept to correct for the amount of air in the lungs was 
introduced by Jones and colleagues in previous studies [154, 179], but is still not a 
fully validated technique. The intercept component of the linear regression, as we 
know, is used to calculate the influx constant from a Patlak plot and represents this 
initial volume of distribution in both the tissue and the blood. Such a correction 
could be particularly significant in the lungs because lung "tissue" on PET images, 
as discussed, includes air and blood as well as the parenchymal tissue itself. 
Changes in density due to atelectasis, pulmonary oedema, or inflammatory 
recruitment of cells might also alter the volume of distribution of 18F-FDG and its 
subsequent rate of uptake. In one such study of a sheep model using bronchoalevolar 
lavage, Prost et al showed that enhanced lung water as in ARDS could generate 
additional volume to distribution to FDG [201]. This volume is not a precursor for 




Thus, optimal ways to correct for such regional variation including the TFE would 
indeed be the compartmental modelling technique, as also shown in my study. This 
technique improved the difference in FDG uptake between controls and COPD. 
 
Using CT data to estimate the air fraction and the compartmental modelling applied 
to lung 18F-FDG data to account for the blood fraction, it is therefore potentially 
possible to quantify the glucose metabolic rate for all lung components (ie, lung 
cells and water) with 18F-FDG PET; hence improving the inflammatory signal from 
the lung. Holman et al has shown in Idiopathic Pulmonary Fibrosis patients that 
without correcting for the TFE, regions of high density (fibrosis) appeared to have a 
higher uptake than lower density (lung with normal appearance on CT scan) 
reinforcing the need to do so [155]. However, this was reversed after air and blood 
correction. Similarly, patients with severe emphysema (with lower density areas) if 
not corrected for the TFE, would arguably give lower uptake signals. This also 
potentially offers an explanation for the higher slope and intercept using 
conventional Patlak analyses, in the healthy control group in my study, which would 
be expected to have higher lung tissue density compared to COPD lungs. 
 
 
4.4.4 Accounting for areas of emphysema 
 
 
Another important facet to consider whilst optimising the signal thus would be to 
account for areas of emphysema in COPD patients. In a study performed by Karimi 
et al smoking volunteers with normal pulmonary function were compared with 
patients with mild to moderate COPD [202]. Higher density spectrum (%HDS), 
which is percentage of pixels in the lung with attenuation between -750 and -900 
HU, were calculated from the inspiratory CT-scans in these subjects. This was then 
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correlated with markers of systemic inflammation and lung inflammation assessed 
by bronchoalveolar lavage. The study showed increased lung density in the healthy 
smokers compared to the COPD patients, and they also recorded that the increased 
lung density on CT was associated with increased inflammatory cell numbers in 
BAL in the healthy smokers. This again emphasises the fact that, in COPD patients 
with emphysema, loss of lung tissue may counterbalance the expected increase in 
inflammation related uptake and supports the importance of correcting for the TFE 
as well as the effect of emphysema when assessing the inflammatory signal in 
COPD patients using dynamic FDG PET scanning. Potentially this also offers an 
explanation as to why the corrected Ki (slope divided by intercept) when corrected 
for areas of emphysema, enhanced the inflammatory signal (corrected Ki) to an 
extent in the COPD patients, compared to the healthy controls using conventional 
Patlak analyses. However, this difference failed to reach statistical significance in 
my study. 
 
In a study by Win et al, the authors compared the FDG PET signal in the normal 
regions of the lungs in IPF patients with controls and found, although only after an 
air fraction correction, that the normal regions of the lung in patients with IPF have 
an increased uptake compared with the lungs of control subjects [203]. This result is 
similar to the results from my study, which showed that removing areas of 
emphysema in the COPD patients and focussing on the non-emphysematous lung 
parenchyma could result in further improvement of FDG lung uptake in COPD 
patients compared with healthy controls. 
 
 
4.4.5 Other potential ways to optimise the signal in in the lungs from 
dynamic FDG PET scanning methodology 
 
The standard methods of calculating Vb from dynamic PET data result in global 
(whole lung) or regional estimates. However, in lung diseases such as COPD where 
the quantity of blood reaching regions of diseased lung is heterogeneous, 
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determination of Vb on a local (voxel-wise) level would be even more 
advantageous. Holman et al applied such a voxel based Vb analyses in IPF patients 
[204]. The study showed the time delay of the image derived input function (IDIF) 
varied considerably between different voxels within the IPF lung (maximum 
difference 17s). This suggests that calculation of a reproducible Vb in the lung 
requires use of a compartment model that accounts for this time delay and ideally 
should be performed on a voxel basis. The computation time for voxel based 
modelling with delay estimation is significant but a similar analysis on the COPD 
cohort would be desirable. 
 
As discussed in the methods chapter, a scale factor of (1-Vb)/(1-Vb-Va) is implicit 
in all methods of kinetic modelling to estimate Ki corrected for air and blood 
volume fractions (since Vb+Va+parenchyma =1). Holman et al [155, 204] and the 
group at University College London (personal communication) recommend removal 
of areas in voxel based parameter images where the tissue fraction (1-Va-Vb) is less 
than 5% to avoid an unrealistic corrected Ki. This may however lead to an 
inaccurate measurement in some COPD patients with severe emphysema, where Va 
could be high resulting in few areas in the lungs with tissue fraction greater than 5%. 
Coello et al claim that their method (qABL method: quantitative analyses which 
correct for the presence of air and blood in the lung) avoids artefactual increase of 
Ki in regions with emphysema [188], but my experience with a similar algorithm is 
that all methods have similar potential problems. Further analysis using a voxel-
based analysis thus could be a way forward. 
 
 
4.4.6 Further factors to consider from the study 
 
 
The results from the dynamic analyses seem to be sensitive to CT density, and 
relaxed expiration attenuation correction CT has been used to assess density in my 
study. However, results using density from an average of full inspiration and relaxed 
expiration (approximating average inspiration) show how density changes the 
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relative corrected Ki in normal and COPD lungs because of different breathing 
patterns. In most COPD patients, relaxed expiration has a similar lung volume to full 
inspiration, but larger differences between full inspiration and relaxed expiration are 
observed in normal subjects. A failure to match the attenuation correction CT with 
average PET in the COPD group properly may have influenced the results. Some 
groups recommend the use of an average of respiratory-gated 4D CT to generate an 
attenuation correction CT, with density equivalent to average PET; but this will 
increase the radiation dose [205]. 
 
Previous studies have also raised concern that a bolus injection of FDG may not lead 
to reliable quantification of the PET data using kinetic modelling analyses [206]. For 
the quantitative evaluation of FDG uptake into the target tissue, kinetic modelling 
utilises the plasma FDG activity-time profile. Results are, therefore, exclusively 
dependent on the uptake kinetics in the studied tissue and are not affected by inter- 
and intra-individual differences in systemic FDG disposition. However, a non- 
homogenous FDG distribution in the blood pool during the first 30 seconds after a 
rapid bolus injection, as was the case in this study, can still lead to errors in the 
measurements.  This is because blood radioactivity in general is not assessed 
directly in the tissue of interest [207]. FDG infusion over a longer duration instead 
of rapid bolus injection might allow for more reliable assessment of the peak in the 
time-activity curve required for Vb estimation in the compartmental model analysis. 
 
 
4.4.7 Comparison between smoker and ex-smoker COPD patients with 
controls 
 
In this study I anticipated that the lung inflammation would be higher in the current 
smoker COPD compared to the ex-smokers, and this has been shown where an 
increased FDG PET uptake, presumably reflecting increased pulmonary 
inflammation, was present in current smoker group compared to the ex-smokers. 
Although the Patlak analysis showed a trend towards increased uptake in the 
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current COPD smokers, the compartmental analyses showed statistically significant 
results in favour of COPD smokers using some of the indices. This is important as it 
reinforces the importance of smoking cessation even in established COPD patients, 
and corroborates the conclusions generated from previous studies that show 
inflammation from persistent smoking in COPD patients is, as expected, associated 
with an increased all-cause mortality rate and exacerbation frequency [51]. 
 
 
4.5 Lobar data analyses 
 
 
In my study, measurement of the FDG signal in the lung lobes showed that the 
upper lobe in COPD patients had a trend towards higher inflammatory signal 
compared to the controls, although this difference failed to reach statistical 
significance. This result is similar to the study performed by Parr et al where they 
showed higher values of corrected Patlak Ki in upper lobes of lungs of COPD 
patients that correlated inversely with per cent predicted FEV1 and positively with 
CT-determined emphysema severity [152]. Since emphysema predominates in the 
upper lobes this might suggest that increased inflammation occurs in association 
with areas of emphysema. However, another explanation might be related to the fact 
that the upper lobes have lower density due to emphysema causing high Patlak 
slope/intercept as intercept correlates with density, as also shown in this study. 
 
In contrast to the findings, Wright et al assessed the pathological abnormalities of 
the small airways in the upper and lower lobes of 13 surgically resected lung 
specimens from COPD patients [208]. The study showed slightly increased degrees 
of respiratory bronchiolar inflammation in the lower lobes compared to the upper 
lobes but no significant differences between the two sites, or any other relationship 
between the presence of pathological abnormalities in the small airways and the 
presence of centrilobular emphysema in these patients. Thus, more detailed lobar 
analyses studies are necessary to understand the regional variation in inflammatory 
uptake in COPD. 
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These conflicting findings also continue to emphasize the need to continue defining 
the relationship of the different 18F-FDG PET quantitative parameters to outcome 
measures; to help determine which metrics are the best surrogate measures of 
inflammation using this methodology. This also reinforces the possibility that 
although corrected Ki using Patlak analyses has been used as the endpoint in many 
previous publications on lung 18F-FDG uptake, it does not adequately account for 
the impact of air and blood in the lungs. The analyses in my study for the lobar data 
were also part of the Patlak methodology and I did not take into account the TFE 
using the compartmental modelling analyses because of time constraints. 
 
 
4.6 Assessment of vascular inflammation 
 
 
My study showed increased vascular (aortic) inflammation in COPD patients 
compared to the controls, when SUVmax was used as index of measurement of 
vascular inflammation. SUVmax was also linked with the severity of the airflow 
limitation as it correlated inversely with the FEV1 per cent predicted. This supports 
the theory that increased vascular inflammation may partly account for the increased 
risk of cardiovascular disease in COPD patients [115, 209]. The underlying 
mechanism is unclear - although elastin degradation may play a role in this 
enhanced inflammation noticed in COPD patients [210]. However, as mentioned 
before, no significant difference was found between the COPD patients and the 
controls when analysing using target to background (TBR: standardized uptake 
value (SUV) normalized to 18F-FDG blood pool activity) as the other index of 
measurement of vascular inflammation. 
 
 
4.6.1 Significance of TBR 
 
 
This is considered an important index of measuring vascular inflammation using 
PET methodology. In a study performed by Vanflettern et al, increased 
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inflammation was shown in the abdominal aorta in COPD patients with lung cancer, 
compared to healthy controls [211]. In this study the parameter chosen to measure 
the aortic inflammation was TBRmax and the TBR was calculated by normalizing 
the arterial SUV for blood pool activity by dividing the SUV values in the arteries 
by the average blood mean SUV estimated from the superior vena cava. However, 
these were patients who had underlying lung cancer that may have influenced the 
results. 
 
Similarly, in another study by Figueroa et al TBR strongly predicted subsequent 
cardiovascular disease in a group of participants who underwent PET-CT for 
oncological evaluation and did not have a prior history of cardiovascular disease, 
independent of traditional risk factors [212], reinforcing TBR as an important 
marker to be considered whilst measuring vascular inflammation. 
 
 
4.6.2 Potential explanation for low TBR 
 
 
In my study the degree of uptake in the aorta was measured at 50 minutes after 18F- 
FDG administration. Most cardiovascular studies recommend assessing vascular 
uptake at a later time-point (60 minutes or later) [213, 214] and might in part explain 
why my TBR readings were lower in the COPD patients. Also, careful selection of 
the index vessel to measure the blood pool activity to calculate TBR is of paramount 
importance [215]. This ensures that the delay between injection of tracer and data 
acquisition, and consequently tracer uptake in the arterial target structure (eg aorta) 
and the washout of tracer from the venous blood pool will be the same for the 
arterial and the venous vessel. The superior venae cava was used as the "index 
vessel" in my study as this was not a vascular tailored study and is very likely to be 
affected by intense uptake of FDG by the myocardium; hence potentially giving 
lower values for the TBR in my study. 
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Although TBR is an important aspect of assessing vascular inflammation, SUVmax 
remains an equally important index of measuring vascular inflammation [216, 217]. 
Therefore, irrespective of the discrepancy of results between the two different 
measures in my study, vascular inflammation is to be expected in COPD patients 
and indeed is independently associated with cardiovascular complications as 
frequently observed in these patients. Intervention studies report a 6-15% reduction 
in markers of aortic inflammation with anti-inflammatory treatments such as anti- 
tumour necrosis-α therapy, or high-dose statins [218, 219] and could form the basis 
of similar such studies in properly vascular tailored studies in COPD. A similar 
prospective analysis thus involving COPD patients and healthy controls, with a 
vascular tailored FDG-PET protocol, analysing SUV and TBR as inflammatory 
indices, using both static and kinetic modelling approach, would be needed to 
determine the association between aortic inflammation and outcomes in COPD. 
 
 
4.7 Summary of the study 
 
In summary my study showed that: 
 Dynamic 18FDG PET scanning is potentially a novel reproducible method of 
assessing for lung inflammation in COPD patients. 
 Image derived methodology is a robust method of deriving arterial input 
functions. 
 The conventional Patlak assessment is not fully adequate to explore the role of 
dynamic PET scanning as a biomarker of lung inflammation, as it does not fully 
account for the effects of lung density and other TFE. My study showed no 
difference in results between COPD and controls using this method. 
 Tissue kinetic modelling is indeed the way of enhancing the signal for lung 
inflammation as it takes account of the air and the blood effect. Using this method 
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my study showed more lung inflammation in COPD patients using some indices, 
compared with control subjects, particularly in COPD patients who were current 
smokers. 
 
4.8 Limitations of the study 
 
 
 One of the major limitations of the study was the sample size that may account 
for the lack of statistical significance for most of the assessments between COPD 
and the healthy controls. This was done primarily to keep the subject number low 
due to associated risk of radiation. A larger study investigating all the methods of 
assessment in a prospective cohort would be desirable.  
 My study showed good reproducibility of all measured indices. However to 
make the methodology even more robust, as mentioned before, inter observer 
measurements would have been ideal. 
 The issues regarding respiratory motion correction have been mentioned 
before. Respiratory-gated analyses using a respiratory motion detector as specified 
earlier would be desirable. 
 The kinetic model analyses technique is sensitive to the location of the volume 
of interest (VOI). In this study I observed that the pulmonary artery image- derived 
arterial input function could have higher peaks than aorta AIFs: higher peak for 
image-derived arterial input functions from the pulmonary artery than from the aorta 
has been shown by other groups too [188]. This higher peak for image-derived 
arterial input functions from the pulmonary artery, than from the aorta, may have an 
implication on Vb estimation and needs further exploration. 
 My study found no correlation of KiPulmVb with any of the markers of serum 
and sputum inflammation. Although a correlation would have been interesting, this 
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is not entirely unexpected. The patients in this study were all scanned during their 
stable state and the inflammation in lung parenchyma that I wanted to demonstrate 
would be expectedly chronic and subtle. Also, all the markers of inflammation that I 
looked into (CRP, Fibrinogen, WCC and the cytokines) are more reflective of 
systemic and airway inflammation (particularly the sputum markers), and therefore 
may not correlate with a PET index of measuring subtle lung parenchymal 
inflammation. A more detailed dynamic PET study in the future encompassing ways 
to look at the airway inflammation would be very informative. 
 Further ways to correct for the TFE when analysing the lobar data using the 
compartmental method of analyses needs exploration. 
 A vascular tailored imaging protocol was not followed in my study as this was 
predominantly a lung study, and could have influenced the results of the vascular 
inflammation. 
 Other disadvantages of 18FDG PET as a biomarker: the PET scan itself entails 
the subjects needing to lie on the scanner for an hour. This adds to the burden of 
motion artefacts and although methods to correct for this have been discussed and 
implemented, it still raises the practicality of using PET scan as a modality of 
measuring lung inflammation in a chronic lung disease cohort.   
 
Also as discussed before, FDG competes with glucose for uptake in the cells and 
any hyperglycaemic state can give potentially false negative FDG uptake [148]. A 
vast majority of the COPD patients can have associated diabetes as comorbidity 
[39,44] and again questions the usefulness of FDG as the most appropriate 




The suitability of FDG (that measures neutrophilic inflammation) in a chronic stable 
lung cohort of COPD, where the inflammation is to an extent also mediated 
thorough macrophages, has already been discussed before.  
 
 
4.9 Future directions 
 
• New PET tracers: Together with a further investigation of the role of 18 F 
FDG, newer radio ligands also hold promise in chronic lung diseases. One such 
radiotracer for inducible nitric oxide synthase (iNOS), 18F (+/−) NOS, could be 
potentially used for imaging inflammation [176]. iNOS is expressed in response to 
inflammatory cytokines [220] and can add to the burden of oxidative stress. 
18F(+/−)NOS is an iNOS-targeted PET tracer that has been tested in an animal  
model of lung inflammation [220] and has shown promise in endotoxin treated lungs 
of healthy volunteers [221]. Given the oxidative stress burden in COPD, this tracer 
potentially holds promise for this cohort. 
 
Similarly, 18F-Fluciclatide has shown promising results for imaging in pulmonary 
fibrosis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity 
for integrins [176]. This has been radiolabeled with F-18 for PET imaging of 
angiogenesis and active fibrosis and assessed in a Phase 1 trial [222]. A recent study 
shows increased 18F-fluciclatide uptake, as quantified using the maximum standard 
uptake value (SUV), in patients with lung fibrosis, compared to healthy volunteers, 
particularly in areas of the lung with the most severe fibrosis [223]. 
 
A translocator protein–targeted tracer 11C-PK11195 has also been used to image the 
presence of macrophages in COPD and asthma patients and age-matched healthy 
controls and compared with 18F-FDG [154]. The study showed increased 
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11CPK11195 activity in both asthmatics and COPD patients in contrast to the 18F-
FDG signal which was increased only in the COPD cohort. The data from this pilot 
study suggest that 11C-PK11195 may be useful in imaging the macrophage burden 
in the lungs. Chen and colleagues showed similar results where they demonstrated 
PET imaging with [11C] PBR28 and [18F] FDG could help to differentiate 
macrophage dominant from neutrophilic inflammation in COPD [224]. This was 
however in an animal model and needs further exploration in human studies. 
 
 Role of combined MR/PET imaging: Without the use of contrast agents, MRI 
provides higher soft-tissue contrast, and therefore holds potential benefits of 
providing superior co-registration of resulting images in comparison to CT scans 
[225]. Radiation exposure is also lower than with hybrid PET/computed tomography 
scanning, and is therefore of added value. The fact that this modality can combine 
the full potential of anatomic and multiparametric imaging of MRI with the 
molecular information of PET could be of immense value to investigate its role as 
an inflammatory biomarker. However, unlike CT attenuation correction where the 
Hounsfield units are directly related to density, attenuation correction for different 
tissues in the human body based on MRI is a major problem [226]. MRI relies on 
the presence of hydrogen nuclei and tissue relaxation properties, rather than on 
tissue densities and a consensus approach to magnetic resonance attenuation 
correction (MRAC) is yet to be agreed on [226, 227]. Nevertheless, this imaging 
technique holds potential and need future further research exploration. 
 Optical imaging using confocal laser endomicroscopy: This diagnostic 
technique aims to look at development of methodologies to attain real-time 
identification of inflammation and infection process in human subjects [228]. 
Several attempts to chemical probe designing and validation have been undertaken 
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so far, however none have yet been successfully translated into clinical practice. A 
combined protocol of dynamic PET imaging with such confocal imaging could 






In conclusion, 18FDG PET scanning holds promise to be used as a novel non- 
invasive biomarker of lung inflammation in COPD patients. The methodology is 
reproducible; careful attention however needs to be given to the tissue fraction effect 
including density effects when interpreting the results of this heterogeneous lung 
disease with chronic subtle lung inflammation. Future prospective analyses of a 
larger number of COPD patients, addressing these issues and investigating all the 
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Section One: supplemental statistical analyses result 
 
Table 1: Wilcoxon scores for variable slope for different modalities of 
input functioning with no statistical difference. 
 
Wilcoxon Scores (Rank Sums) for Variable Slope 













Image derived 6 63.0 81.00 16.431 10.50 
Venous blood 5 60.0 67.50 15.370 12.00 
Venous plasma 5 43.0 67.50 15.370 8.60 
Arterial blood 5 98.0 67.50 15.370 19.60 





Pr > Chi-Square 0.1054 
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Table 2: Wilcoxon scores for variable intercept for different modalities 
of input functioning with no statistical difference between all the 
methods (p value 0.35). 
 
Wilcoxon Scores (Rank Sums) for Variable Intercept 













Image derived 6 89.0 81.00 16.431 14.833 
Venous blood 5 91.0 67.50 15.370 18.200 
Venous plasma 5 63.0 67.50 15.370 12.600 
Arterial blood 5 66.0 67.50 15.370 13.200 











Table 3: Non-parametric analyses of the slope data using Wilcoxon 
scores between visit 1 and 2 also showing no statistical difference (p 
value 0.36). 
 
Wilcoxon Scores (Rank Sums) for Variable Slope 













2 17 330.0 365.50 39.024 19.411 






Pr > Chi-Square 0.3630 
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Table 4: Non-parametric analyses of the intercept data using Wilcoxon 
scores between visit one and two also showing no statistical 
significance (p value 0.09). 
 
 
Wilcoxon Scores (Rank Sums) for Variable Intercept 













2 17 300.0 365.50 39.024 17.647 










Table 5: Patlak slope in COPD patients and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable Intercept 













COPD 19 222.0 247.0 15.716234 11.684 






Pr > Chi-Square 0.1117 
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Table 6: Patlak intercept in COPD patients and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable Intercept 













COPD 19 192.0 247.0 15.716 10.105 












Table 7: Comparative data (slope/intercept) between the two visits of 
the COPD patients. 
 
 
Wilcoxon Scores (Rank Sums) for Variable Slope/ Intercept 













2 17 362.0 365.50 39.024 21.294 





Pr > Chi-Square 0.98 
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Table 8: shows no significant difference of slope/intercept between 
COPD and controls (p value 0.70). 
 
 
Wilcoxon Scores (Rank Sums) for Variable Slope/ Intercept 













COPD 19 241.0 247.0 15.716 12.684 










Table 9: Comparison of KiAoVb between visits 1 and 2. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiAoVb 













1 14 503.0 500.00 34.156 20.120 





Pr > Chi-Square 0.9300 
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Table 10: Comparison of KiPulmVb between visits 1 and 2. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiPulmVb 













1 25 511.0 500.00 34.156 20.440 











Table 11: Comparison of KiAoVbVa between visits 1 and 2. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiAoVbVa 













1 25 490.0 500.00 34.156 19.600 





Pr > Chi-Square 0.769 
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1 25 506.0 500.00 34.156 20.240 













Table 13: KiAoVb between COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiAoVb 













COPD 25 397.0 400.0 20.0 15.880 





Pr > Chi-Square 0.86 
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Table 14: KiaAoVbVa between COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiAoVbVa 













COPD 25 410.0 400.0 20.0 16.400000 











Table 15: KiPulmVb between COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiPulmVb 













COPD 25 440.0 400.0 20.0 17.600000 






Pr > Chi-Square 0.04 
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Table 16: KiPulmVbVa between COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for Variable KiPulmVbVa 













COPD 25 435.0 400.0 20.0 17.400000 










Table 17: Comparison of SUVmax between visits 1 and 2. 
 
 
Wilcoxon Scores (Rank Sums) for SUV Max 














2 18 350.0 396.00 40.620192 19.444444 






Pr > Chi-Square 0.2574 
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Table 18: Comparison of SUVmax between COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for SUVmax 













COPD 19 269.0 247.00 15.716234 14.157895 











Table 19: Comparison of SUVcorrDENS corrected for density between 
COPD and controls. 
 
 
Wilcoxon Scores (Rank Sums) for SUVcorrDENS 













COPD 19 277.0 247.00 15.716234 14.578947 







Pr > Chi-Square 0.0563 
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Table 20: Comparison of SUV corrected density using kinetic 
modelling analyses between COPD and controls. 
 
Wilcoxon Scores (Rank Sums) for SUVaoDENS 













COPD 25 440.0 400.00 20.0 17.600 











Section Two: principles of running an ELISA 
experiment 
 
ELISA protocol commences with a capture antibody, specific for a protein of 
interest, coated onto the wells of microplates. Samples, including a standard 
containing protein of interest, control specimens, and unknowns, are pipetted into 
these wells. During the first incubation, the protein antigen binds to the capture 
antibody. After washing, a detection antibody is added to the wells, and this 
antibody binds to the immobilized protein captured during the first incubation. 
After removal of excess detection antibody, an HRP conjugate (secondary antibody) 
is added and binds to the detection antibody. After a third incubation and washing to 
remove the excess HRP conjugate, a substrate solution is added and is converted by 
the enzyme to a detectable form (colour signal). The intensity of this coloured 
product is directly proportional to the concentration of antigen present in the original 
specimen. 
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1. Sputum selection: Before processing the sample, discard the specimen cup 
containing the salivary portion of the expectorate to avoid potential confusion with 
the sample specimen waste cup. The sputum sample is poured into a Petri dish for 
visual examination or inspection. The colour (clear, yellow, green), purulence and 
signs of blood contamination are noted in the CRF (Sputum Sample Quality page). 
The Petri dish should then be placed on a dark background. All solid or dense 
looking material as compared to clear surrounding fluid is defined and referred to as 
"sputum plug". Plugs are typically gelatinous (more dense) and mucoid in 
appearance. Using fine or pointed sterile forceps, select the sputum plugs from the 
saliva and transfer them onto the Petri dish lid. If blood is in the sample, avoid 
selecting it. Then, using larger blunt ended forceps, gather the sputum plugs into one 
mass and then condense by moving the entire mass around the lid in circular 
motions.  The aim is to spread the saliva around the lid but to keep sputum in one 
mass. Transfer the concentrated sputum with the blunt ended forceps to a pre- 
weighed 15 ml polypropylene centrifuge tube with screw top (use of polystyrene 
tubes is not recommended as they cause cell adhesion). The selection procedure and 
condensation/removal of saliva are important in reducing squamous cell 
contamination. In order to further reduce  contamination with squamous epithelial 
cells, it can be helpful (but not necessary) to use an inverted microscope to help in 
identifying the plugs in the sputum sample. It is also helpful to hold the Petri dish up 
to the light and look through the bottom of it in order to see whether plugs are 




Sputum weight: Once all the plug material has been selected and placed into a 
15ml polypropylene test tube, record the weight of the test tube using a 
microbalance or scale that is accurate to at least 2 decimal places. The weight of the 
selected plug is determined by subtracting the weight of the test tube from the 
weight of the test tube + sputum plug and this weight is recorded on the CRF. A 
minimum of 0.5 g of selected sputum is recommended to enable the sample to be 
fully processed (but 0.15 g may suffice). Keep the sample tube on ice and make sure 
it is processed as soon as possible (within 2 hours). 
 
2. Addition of DTT: A ratio of 4:1, of ml of 0.1% DTT: grams of sputum plug 
is necessary (ie, 0.1% DTT is added to the sputum in the ratio of 4ml DTT to 1g 
sputum plugs). Please see the example in Appendix 2. 
 
3. Liquefaction: Following the addition of DTT, the sample is vortexed for 15 
seconds and aspirated with a pipette if necessary to ensure thorough homogenization 
(mixing) of the sample (ie, no visible clumps still suspended in solution). The 
sample is then agitated on a rotating tumbler for 15 minutes at room temperature. If 
a rotating tumbler is not available, one can use a rolling mixer or rocker. 
 
**NOTE: It is important to be exact with the 15-minute incubation in DTT - do 
not extend this incubation period as prolonged incubation with DTT can be 
detrimental to the sample. At the end of the 15-minute incubation period, DPBS 
(or PBS) in the same volume as the 0.1% DTT volume is added to the sample. The 





4. Filtration: **NOTE: This filtration step may need to be repeated if the 
sample is large. Mucus can block the mesh and a new filter is needed for the 
remaining sample. 
Once the tumbling is complete, the sample is filtered through a 48-55 µm pore nylon 
mesh filter (that sits in a conical plastic funnel) into a 50ml polypropylene test tube. 
It is advisable to pre-wet the mesh filter with DPBS/PBS so that it adheres to the 
sides of the funnel. Do not let the filter fold over onto itself or form creases. The 
bottom of the filter should be as flat and smooth as possible. If 48-55 µm pore nylon 
mesh filter is not available, a BD Falcon Cell Strainer may be used. 
 
**NOTE: A BD Falcon Strainer should only be used with 50ml tubes if the 
sample is of large enough volume. 
 
Use a pipette (1ml) to deliver the sample through the filter and do not aggressively 
discharge the sample onto the filter. The sample should ideally drip through the 
filter and not "run" through it. 
 
5. Centrifugation of filtrate: Once the filtrate is collected it is centrifuged at 
4OC for 5 minutes at 1000 rpm (400-500 x g, depending on centrifuge, it may be 
necessary to spin for up to 10 min at 2000 rpm) to precipitate the cells into a soft 
pellet. Use a pipette to remove the supernatant layer.  The pellet may or may not be 
visibly obvious so take care not to disturb it when pipetting out the supernatant 
layer. 
 
**NOTE: Do not decant (tip) the sample tube to remove the supernatant. If a 
layer of mucus is observed at the top of the tube following centrifugation, it should 
be removed with a pipette tip prior to removing the supernatant. 
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6. Supernatant aliquots: The supernatant should be aliquoted into pre-chilled 
labelled screw-cap 2ml polypropylene cryotubes with blue snap cap inserts; ideally 
3 aliquots of not less than 200 ul each should be obtained (if less than 600 ul is 
produced then less aliquots should be provided to maintain the volume of each 
aliquot). All sputum supernatant aliquots should be labelled and stored at -70ºC until 
required for analysis. 
 
Aliquot 1: 200 ul (biomarkers). Label from Sample Data Sheet 3, Line 46. Indicate 
the relevant sample code. Record the box and position of the aliquot. Aliquot 2: 
diluted (25x) sputum supernatant aliquot for MPO analysis. In a cryotube add 50 ul 
of fresh sample into 1200 ul of stabilizing buffer (provided by GSK). 
Label from Sample Data Sheet 3, Line 48. Indicate the relevant sample code. Record 
the box and position of the aliquot. 
 
Aliquots 3 and 4: 2ml of the remainder is added to each tube (add protease inhibitor 
at 10µl/mL). 
 
Label from Sample Data Sheet 3, Line 47. Indicate the relevant sample code. Record 
the box and position of the aliquots. 
 
7. Re-suspension: Immediately following removal of the supernatant, the cell 
pellet must be fully re-suspended in an appropriate volume of cold PBS to ensure 
that it does not dry out. It is recommended that the sample pellet be re- suspended to 
give a concentration of approximately 500,000 cells/ml. The volume required is 
usually between 0.3 and 1.0 ml, depending on the size and viscosity of the pellet. A 
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more thick or viscous pellet would require a higher re- suspension volume closer to 
1ml (and on some occasions, larger pellets require 1.5ml). Once the buffer is added 
to the pellet, it is mixed by gentle vortexing using cell saver tips or gentle pipette 
aspiration.  Keep the cell suspension on ice while performing the next step: quick 
cell counting (within 15 min). 
 
8. Quick Cell count: Assess total cell count for viability and qualitative level of 
squamous cell contamination using a Neubauer haemocytometer. 
**NOTE: The New Improved Bright Line Neubaur Haemocytometer is 
recommended) and the Trypan Blue exclusion method, as follows: 
• First locate the Neubauer haemocytometer and make sure it is clean, has a 
cover slip and is ready for use. It is strongly recommended that the haemocytometer 
and coverslip are cleaned with 70% ethanol or methanol to ensure better quality 
when counting. 
• Remove a 10 µl aliquot of the cell suspension and mix it with 10 µl of 0.4% 
Trypan blue in an eppendorf tube. Trypan blue is commercially purchased as a 0.4% 
solution (so there is no need to dilute it). 
• Gently aspirate the sample using a pipette 2-3 times to ensure good mixing. 
• Place the cover slip on top of the haemocytometer (a number 1 cover slip is 
used). Formation of Newton's rings between the external support and the cover slip 
shows that the cover slip is correctly positioned. Inject 10µl of the stained mixture 
into one end (injection port) of the haemocytometer and repeat for the other 
injection port. Be careful not to flood the chamber of the hemcytometer (a 10µl 
volume should adequately fill the chamber and not overflow it). 
 
**NOTE: Introduction of bubbles may occur when aspirating the sample to 
mix with the Trypan Blue dye and when loading the haemocytometer. This 
184  
should be avoided as much as possible as bubbles may have a large impact on cell 
count. 
 
Place the haemocytometer under the microscope for cell counting. Perform a cell 
count within 5 minutes, following the instructions outlined below. Find the counting 
grids (four 4x4 square grids in each corner quadrant with a more detailed centre 
grid) by adjusting the focus of the microscope (usually 20x magnification power is 
enough to see the grid lines). Initially focus the grid based on the clarity of the grid 
lines and not the cells. Use the upper left 4x4 quadrant grid as the starting grid for 
your cell counts. 
9. Cytospin slide preparation: Assemble the cytospin slide apparatus 
(microscope slide, filter paper, sample bucket, and metal/plastic clip). Make sure 
that the filter card circle lines up with the filter cup circle by observing the reverse 
side of the metal/plastic clip when assembled (See the cytospin instructions if you 
are unsure). Disposable cytofunnels (filter paper and sample bucket) are available 
and are recommended in order to reduce potential contamination and avoid 
disinfection steps. Please see the manufacturer’s instructions regarding the type of 
cytospin apparatus you have. It is recommended to use single cytofunnels (i.e. filter 
papers with one hole) and not the double cytofunnels (2 holes). 
 
Adjust the sample suspension to any concentration between 0.5- 1.0 x 106 cells/ml 
using DPBS or PBS. See Appendix 2 for examples of how to do this. Prepare 2 
slides for differential cell staining. Please ensure these slides are affixed with the 
correct label (use of a lead pencil is recommended as this will not come off when the 
slides are being stained). 
 
Add 65µl of cell suspension to the cytospin bucket. Deposit the 65µl of sample 
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directly at the bottom of the bucket (ie, do not let it drip down the sides to settle on 
the bottom). 
 
**NOTE: The volume of cell suspension to be added to the cytospin should be 
65 µl if the cell concentration is close to the 1 x 106 cells/ml. The volume should 
be increased to 100 µl if the sample concentration is closer to the 0.5 x 106 
cells/ml level. Load the cytospin slide apparatus with the two slides into the 
centrifuge making sure that the centrifuge is appropriately balanced before spinning. 
Set the cytospin at 450 rpm with medium acceleration for 6 minutes. The remaining 
sample should be kept on ice during this time. 
 
When the cytospin is finished, carefully and quickly remove each slide apparatus 
and remove the slide from the assembly. Be sure not to disturb the sample pellet 
(which will appear as a round dot of sample) on the slide. Let the slides air dry for at 
least 15 minutes. 
 
At this stage the slide quality and density should be checked under a microscope to 
ensure the quality of your samples. 
 
10. Differential cell staining: Following air-drying, the 2 slides are stained 
according to the manufacturer's instructions for the stain kit used. 
 
**NOTE: Please follow manufacturer's instructions of the kit you are using. 
Once the slides have been stained and air dried, mount with DPX (or similar 
mounting media) and size 0 cover slips, store at room temperature. 
 
• Label: Affix each slide on the side with the appropriate bar code label taken 
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from Sample Data Sheet (SDS) 3, lines 50 and 51. Indicate the relevant sample code 
on the SDS. 
 
 
Storage of sputum supernatant and cell samples for analysis 
The sputum supernatants and cell TRIzol lysate and slides will be stored at -70o C 
(supernatant, TRIzol lysate) and room temperature (slides) for shipment as 
described above. The number of aliquots of supernatant and TRIzol lysate is 
recorded in the CRF. 
 
Modified MRC score: 
 
